

NAME: MIGUEL VIVEIROS BETTENCOURT
DATE OF BIRTH: 18th October 1966
NATIONALITY: Portuguese
ADDRESS: Group of Micobacteriology
Unit of Medical Microbiology
Instituto de Higiene e Medicina Tropical
Global Health and Tropical Medicine
Universidade NOVA de Lisboa
Rua da Junqueira, 100
P-1349-008 LISBOA
PORTUGAL
Tel.: (21) 365 26 53
Fax: (21) 363 21 05
E-mail: mviveiros@ihmt.unl.pt



ACADEMIC QUALIFICATIONS :

- 1991 Degree in Biology from Faculdade de Ciências da Universidade de Lisboa (FC/UL)
- 1995 Master of Science in Biotechnology (Biochemical Engineering) from Instituto Superior Técnico da Universidade Técnica de Lisboa (IST/UTL)
- 2001 PhD in Biology (Microbial Genetics) from Faculdade de Ciências da Universidade de Lisboa
- 2012 Habilitation in Biomedical Sciences (Speciality Microbiology) - (Agregação em Ciências Biomédicas – Especialidade Microbiologia) from Instituto de Higiene e Medicina Tropical/ Universidade Nova de Lisboa.

APPOINTMENTS AND WORKING ACHIEVEMENTS:

Oct/1991 - Sep/1992 - Research training in Virology ; Supervision: Prof^a Wanda Canas-Ferreira; Laboratory: Departamento de Microbiologia do Instituto de Higiene e Medicina Tropical da Universidade Nova de Lisboa (IHMT/UNL); Subject: "Cell culture for HIV-2 isolation from Guinea-Bissau "
Lecturing Post-Graduation Course in Tropical Medical Microbiology.

Oct/1992 - Apr/1995 - Master of Science Course in Biotechnology (Biochemical Engineering) from IST/UTL and research activity in Molecular Genetics/Biotechnology with a Scholarship from Junta Nacional de Investigação Científica e Tecnológica (J.N.I.C.T./F.C.T.); Supervision: Prof^a Doutora Isabel Sá-Correia (IST/UTL) and Prof Dr. Hugo Ayres David (Institut Pasteur Paris); Laboratory: Microbiologia IHMT/UNL; Thesis: "Carotenogenesis in Mycobacterium vaccae - Genetic and biochemical characterization"

Apr/1995 – Mar/2001 - PhD Scholarship from J.N.I.C.T./F.C.T.; Supervision: Prof Dr. Hugo Ayres David (Institut Pasteur Paris and IHMT/UNL) and Prof. Dr. Filomena Exposto (IHMT/UNL); Laboratory: Microbiologia of IHMT/UNL.; Thesis: "Isolation of the carotenogenesis operon in Mycobacterium vaccae. - Application to the development of new mycobacterial genetic tools and to the understanding of molecular mechanism of tuberculosis pathogeny"

Jan/1998 – Mar/2001 - Lecturer (Assistente) in Medical Microbiology/Bacteriology in the Unit of Mycobacteriology of the IHMT/UNL. Lecturing activities in the Post-Graduation Course in Tropical Medical Microbiology and in the Faculty of Medical Sciences (Universidade Nova de Lisboa) – Microbiology and Parasitology -Third year of the Medical Degree Course. Research activities in Molecular Genetics of Mycobacteria, mycobacteria diagnosis and drug resistance.

Mar/2001 –Dec2009 - Assistant Professor (Professor Auxiliar) in Medical Microbiology/Bacteriology in the Unit of Mycobacteriology of the IHMT/UNL . Lecturing activities in the Masters Course (MSc) in Medical Microbiology from the IHMT/UNL; MSc Coordinator since 2003. Deputy Director of the Tuberculosis and Mycobacteria Clinical Laboratory. Research activities in Molecular Genetics of Mycobacteria and Bacteria, mycobacteria diagnosis, drug resistance and development of new drugs.

Dec2009 - April 2012 – Associate Professor (Professor Associado) in Medical Microbiology/Bacteriology in the Unit of Medical Microbiology (Group of Mycobacteriology) of the IHMT/UNL

April 2012 to July 2013 - Associate Professor with Habilitation in Biomedical Sciences (Speciality Microbiology) (Professor Associado com Agregação em Ciências Biomédicas – Especialidade Microbiologia) in the Unit of Medical Microbiology (Group of Mycobacteriology) of the IHMT/UNL. Thesis: “As novas tecnologias de biologia molecular no diagnóstico precoce da tuberculose resistente: a sua integração e monitorização no contexto dos programas de controlo da tuberculose - The new molecular biology technologies in the early diagnosis of drug-resistant tuberculosis: its integration and monitoring in the context of TB control programs”.

July 2013 to date - Full Professor in Medical Microbiology (Professor Catedrático em Microbiologia Médica) in the Unit of Medical Microbiology (Group of Mycobacteriology) of the IHMT/UNL.

January 2010 to date – President of the Pedagogical Council of the IHMT/UNL.

October 2014 – October 2017 – Special Visiting Professor at Faculdade de Medicina da Universidade do Rio de Janeiro (Brasil). Ref _ CAPES218488

Teaching Activity (coordination and/or teaching):

Mestrado (2º Ciclo) em Microbiologia Médica da Universidade Nova de Lisboa (UNL) – MSc in Medical Microbiology of UNL. Curricular Unit of Medical Bacteriology and Curricular Unit of Tuberculosis and other Mycobacteriosis;

Mestrado (2º Ciclo) em Ciências Biomédicas (IHMT/UNL) – MSc in Biomedical Sciences of IHMT/UNL. Curricular Unit of Medical Microbiology;

Mestrado (2º Ciclo) em Saúde Tropical (IHMT/UNL) – MSc in Tropical Health. Lectures on Laboratory Diagnosis of Tuberculosis and Curricular Unit of Tuberculosis and other Mycobacteriosis;

Mestrado (2º Ciclo) em Saúde e Desenvolvimento (IHMT/UNL) – MSc in Health and Development. Lectures on Design of TB-Control programs;

Doutoramento (3º Ciclo) em Ciências Biomédicas (IHMT/UNL). PhD in Biomedical Sciences - Curricular Unit of Medical Microbiology and Curricular Unit of Tuberculosis and other Mycobacteriosis;

Doutoramento (3ºCiclo) em Genética Humana e Doenças Infeciosas (IHMT/UNL) – PhD in Human Genetics and Infection. Curricular Unit of Medical Microbiology and Mycology.

Area of scientific activity: Scientific activity devoted to the early diagnosis of active or latent tuberculosis (TB) infections as well as the development of new therapeutical approaches to deal with MDRTB and with other drug resistant bacterial infections. Also interested in molecular biology of mycobacteria and immunology of TB. Executive Co-ordinator of the Masters in Medical Microbiology of the UNL. As Deputy-Director of the TB Laboratory of the IHMT (since 2001) has contributed to the resolution of the pulmonary TB problem of Lisbon by the generation of complete reports within a period of 15 to 20 days for 10 Hospitals of the TB Task Force of Lisbon. Over 100 studies published in peer review national and international journals in mycobacteriology, bacteriology, and resistance to antibiotics, microbial genetics, molecular epidemiology and immunology.

Domain of specializations: Medical Microbiology, bacteriology, mycobacteriology, laboratory diagnosis of mycobacterial infections, molecular biology and genetics of *Mycobacterium* sp. Tuberculosis. Molecular typing of multidrug-resistant *Mycobacterium tuberculosis*. Mechanisms and strategies to circumvent drug resistance in mycobacteria, composition of the mycobacterial cell wall/envelope in relation to drug resistance, new antibiotics, antibiotic uptake, efflux-pumps, drug targeting and molecular vectorisation, nanotechnology, flow-cytometry.

Present research interests: Research in tuberculosis and antibiotic resistant infections in support for alternative therapies of incurable diseases such as multidrug resistant tuberculosis and methicillin-vancomycin resistant staphylococcal infections. Immunology of tuberculosis. Strong interests in assisting Portuguese speaking countries of Africa in combating tuberculosis. Expertise in the laboratory diagnosis of tuberculosis infections.

Research funding : Principal Investigator/Team Leader of 8 research projects (and member the team of 12 other research projects). Funding Agencies: Fundação para a Ciência e a Tecnologia, Ministério da Educação e Ciência, Fundação Calouste Gulbenkian, Ministério da Saúde, Conselho de Reitores das Universidades Portuguesas (Portugal), European Union.

Refereeing activities : Member of the evaluation panel of Individual Doctoral and Post-doctoral Grant proposals - area Biomedical Sciences and Basic Medicine -2013-2015 -Fundação para a Ciência e a Tecnologia – Ministério da Educação e Ciência de Portugal. Expert Evaluator for the “MRC South Africa 2013- 2014” calls (area Tuberculosis). Member of the Review and Advisory Panel of the ‘Wellcome Trust Awards 2014”. Ad-hoc reviewer for the expert panel of the The Research Foundation – Flanders (FWO), Belgium. Member of the evaluation panels for the QREN R&D investment proposals of the Ministério da Economia de Portugal. Consultant of the Ministério da Saúde de Portugal (Área Tuberculosis). Regular ad-hoc reviewer of several international journal manuscripts (JAC, AAC, PlosOne, IJAA, Tuberculosis, BMC Microbiology, etc) .

Academic and Science Management activities:

2010 – present - President of the Pedagogical Council of the IHMT/UNL.

2005 – present - Elected member and Vice-President of the General Council of the IHMT/UNL.

2009 - present - Elected member of the Scientific Council of the IHMT/UNL.

2006 - 2014 – Member of the Directive Committee of the Portuguese Board of Biologists (Ordem dos Biólogos)

2010 - 2014 - Founding member and Treasurer of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Group for Mycobacterial Infections (ESGMYC).

<https://www.escmid.org/index.php?id=897>

Elected Vice-chair of the Gordon Research Conference - Multi-Drug Efflux Systems - 2017-2019

BIBLIOMETRICS:

ISI - Web of Knowledge analysis: Total Articles in Publication List: 128; Articles With Citation Data: 112; Sum of the Times Cited: 2241; Average Citations per Article: 20.01

h-index: 30

ResearcherID: A-7326-2008

URL: <http://www.researcherid.com/rid/A-7326-2008>

Scopus analysis:

Total Articles in Publication List: 125

Sum of the Times Cited: 2700

h-index: 32

Scopus Affiliation : 7003949212

URL : <http://www.scopus.com/authid/detail.url?authorId=7003949212>

Google Scholar webpage:

Total citations: 3625

h-index: 37

URL : <http://scholar.google.pt/citations?user=o39byr4AAAAJ&hl=en>

ORCID ID :

URL : <http://orcid.org/0000-0001-9676-6251>

PUBLICATIONS IN INTERNATIONAL PEER-REVIEW JOURNALS (N = 123):

1. Dalla Costa ER, Vasconcelos SE, Esteves LS, Gomes HM, Gomes LL, Almeida da Silva P, Perdigão J, Portugal I, Viveiros M, McNerney R, Pain A, Clark TG, Rastogi N, Unis G, Rossetti ML, Suffys PN. Multidrug resistant *Mycobacterium tuberculosis* of the Latin American Mediterranean lineage wrongly identified as *Mycobacterium pinnipedii* (ST863) causing active tuberculosis in south Brazil. *J Clin Microbiol*. 2015 Sep 23. pii: JCM.02012-15. <http://www.ncbi.nlm.nih.gov/pubmed/26400784>
2. Pieroni M, Machado D, Azzali E, Santos Costa S, Couto I, Costantino G, **Viveiros M**. Rational Design and Synthesis of Thioridazine Analogues as Enhancers of the Antituberculosis Therapy. *J Med Chem*. 2015 Aug 13;58(15):5842-53. doi: 10.1021/acs.jmedchem.5b00428. <http://pubs.acs.org/doi/abs/10.1021/acs.jmedchem.5b00428>
3. Coll F, McNerney R, Preston MD, Guerra-Assunção JA, Warry A, Hill-Cawthorne G, Mallard K, Nair M, Miranda A, Alves A, Perdigão J, **Viveiros M**, Portugal I, Hasan Z, Hasan R, Glynn JR, Martin N, Pain A, Clark TG. Rapid determination of anti-tuberculosis drug resistance from whole-genome sequences. *Genome Med*. 2015 May 27;7(1):51. doi: 10.1186/s13073-015-0164-0. <http://www.genomemedicine.com/content/7/1/51>
4. Rabna P, Ramos J, Ponce G, Sanca L, Mané M, Armada A, Machado D, Vieira F, Gomes VF, Martins E, Colombatti R, Riccardi F, Perdigão J, Sotero J, Portugal I, Couto I, Atouguia J, Rodrigues A, **Viveiros M**. Direct Detection by the Xpert MTB/RIF Assay and Characterization of Multi and Poly Drug-Resistant Tuberculosis in Guinea-Bissau, West Africa. *PLoS One*. 2015 May 27;10(5):e0127536. doi: 10.1371/journal.pone.0127536. <http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0127536>
5. Coelho T., Machado D., Couto I., Maschmann R., Ramos D., Von_groll A, Rossetti ML, Silva PA, **Viveiros M**. Enhancement of antibiotic activity by efflux inhibitors against multidrug resistant *Mycobacterium tuberculosis* clinical isolates from Brazil. *Frontiers in Microbiology*, 2015. 6:330 <http://journal.frontiersin.org/article/10.3389/fmicb.2015.00330/abstract>
6. Cabral V, Luo X, Junqueira E, Costa SS., Mulhovo S, Duarte A, Couto I, Viveiros M, Ferreira MJU. Enhancing activity of antibiotics against *Staphylococcus aureus* by *Zanthoxylum capense* constituents and derivatives. *Phytomedicine* . 2015. 22:4, 469-476 <http://www.sciencedirect.com/science/article/pii/S0944711315000495#>
7. Cambau E, **Viveiros M**, Machado D, Raskine L, Ritter C, Tortoli E, Matthys V, Hoffner S, Richter E, Perez Del Molino ML, Cirillo DM, van Soolingen D, Böttger EC. Revisiting susceptibility testing in MDR-TB by a standardized quantitative phenotypic assessment in a European multicentre study. *J Antimicrob Chemother*. 2015 Mar;70(3):686-96. doi: 10.1093/jac/dku438. <http://jac.oxfordjournals.org/content/early/2014/11/11/jac.dku438.short>
8. Rodrigues L, **Viveiros M**, Aínsa JA. Measuring efflux and permeability in mycobacteria. *Methods Mol Biol*. 2015;1285:227-39. doi: 10.1007/978-1-4939-2450-9_13. http://link.springer.com/protocol/10.1007%2F978-1-4939-2450-9_13
9. Costa P, Couto I, **Viveiros M**, Inácio J. Nested and multiplex real-time PCR using dual-labeled probes: detecting and discriminating *Mycobacterium tuberculosis* complex members in cultures and animal tissues. *Methods Mol Biol*. 2015;1247:133-43. doi: 10.1007/978-1-4939-2004-4_9. http://link.springer.com/protocol/10.1007/978-1-4939-2004-4_9#page-1

10. Costa P, Botelho A, Couto I, **Viveiros M**, Inácio J. Standing of nucleic acid testing strategies in veterinary diagnosis laboratories to uncover *Mycobacterium tuberculosis* complex members. *Front. Mol. Biosci.*, 2014 Oct 15; 1:16. doi: 10.3389/fmolb.2014.00016.
<http://journal.frontiersin.org/Journal/10.3389/fmolb.2014.00016/full>
11. Costa P, Amaro A, Ferreira AS, Machado D, Albuquerque T, Couto I, Botelho A, **Viveiros M**, Inácio J. Rapid identification of veterinary-relevant complex species using 16S rDNA, IS6110 and Regions of Difference-targeted dual-labelled hydrolysis probes. *J Microbiol Methods*. 2014 Sep 2;107C:13-22. doi: 10.1016/j.mimet.2014.08.017.
<http://www.sciencedirect.com/science/article/pii/S0167701214002516>
12. Perdigão J, Silva H, Machado D, Macedo R, Maltez F, Silva C, Jordao L, Couto I, Mallard K, Coll F, Hill-Cawthorne GA, McNerney R, Pain A, Clark TG, **Viveiros M**, Portugal I. Unraveling *Mycobacterium tuberculosis* genomic diversity and evolution in Lisbon, Portugal, a highly drug resistant setting. *BMC Genomics*. 2014 Nov 18;15:991. doi: 10.1186/1471-2164-15-991.
<http://www.biomedcentral.com/1471-2164/15/991>
13. Leão C, Canto A, Machado D, Sanches IS, Couto I, **Viveiros M**, Inácio J, Botelho A. Relatedness of *Mycobacterium avium* subspecies *hominissuis* clinical isolates of human and porcine origins assessed by MLVA. *Vet Microbiol*. 2014 Sep 17;173(1-2):92-100. doi: 10.1016/j.vetmic.2014.06.027.
<http://www.sciencedirect.com/science/article/pii/S0378113514003198>
14. Coll F, McNerney R, Guerra-Assunção JA, Glynn JR, Perdigão J, **Viveiros M**, Portugal I, Pain A, Martin N, Clark TG. A robust SNP barcode for typing *Mycobacterium tuberculosis* complex strains. *Nature Communications*. 2014 Sep 1;5:4812. doi:10.1038/ncomms5812.
<http://www.nature.com/ncomms/2014/140901/ncomms5812/full/ncomms5812.html>
15. Martins F, Santos S, Ventura C, Elvas-Leitão R, Santos L, Vitorino S, Reis M, Miranda V, Correia HF, Aires-de-Sousa J, Kovalishyn V, Latino DA, Ramos J, **Viveiros M**. Design, synthesis and biological evaluation of novel isoniazid derivatives with potent antitubercular activity. *Eur J Med Chem*. 2014 Jun 23;81:119-38. doi: 10.1016/j.ejmech.2014.04.077.
<http://www.sciencedirect.com/science/article/pii/S0223523414004061>
16. Perdigão J, Macedo R, Machado D, Silva C, Jordão L, Couto I, **Viveiros M**, Portugal I. GidB mutation as a phylogenetic marker for Q1 cluster *Mycobacterium tuberculosis* isolates and intermediate-level streptomycin resistance determinant in Lisbon, Portugal. *Clin Microbiol Infect*. 2014 May;20(5):O278-84. doi: 10.1111/1469-0691.12392. doi: 10.1111/1469-0691.12392.
<http://onlinelibrary.wiley.com/doi/10.1111/1469-0691.12392/pdf>
17. Coll F, Preston M, Guerra-Assunção JF, Hill-Cawthorn G, Harris D, Perdigão J, **Viveiros M**, Portugal I, Drobniowski F, Gagneux S, Glynn JR, Pain A, Parkhill J, McNerney R, Martin N, Clark TG. PolyTB: A genomic variation map for *Mycobacterium tuberculosis*. *Tuberculosis*. 2014 May;94(3):346-54. doi: 10.1016/j.tube.2014.02.005.
<http://www.sciencedirect.com/science/article/pii/S1472979214203428>
18. Pedrosa P, Veigas B, Machado D, Couto I, **Viveiros M**, Baptista PV. Gold nanoprobe for multi loci assessment of multi-drug resistant tuberculosis. *Tuberculosis*. 2014 May;94(3):332-7. doi: 10.1016/j.tube.2013.12.009.
<http://www.sciencedirect.com/science/article/pii/S147297921400002X>
19. **Viveiros M**, Pieroni M. Spectinomides: a challenge, a proof, and a suggestion. *Trends in Microbiology*. 2014 Apr;22(4):170-1. doi: 10.1016/j.tim.2014.02.008.
<http://www.sciencedirect.com/science/article/pii/S0966842X14000420>

20. Machado D, Ramos J, Couto I, Cadir N, Narciso I, Coelho E, Viegas S, **Viveiros M**. Assessment of the BD MGIT TBc Identification Test for the Detection of *Mycobacterium tuberculosis* Complex in a Network of Mycobacteriology Laboratories. *BioMed Research International*, 2014;2014:398108. doi: 10.1155/2014/398108. <http://www.hindawi.com/journals/bmri/2014/398108/abs/>
21. Martins F, Ventura C, Santos S, **Viveiros M**. QSAR Based Design of New Antitubercular Compounds: Improved Isoniazid Derivatives Against Multidrug-Resistant TB. *Curr Pharm Des*. 2014;20(27):4427-54. doi: 10.2174/1381612819666131118164434 <http://www.eurekaselect.com/118061/article>
22. de Carvalho CC, Costa SS, Fernandes P, Couto I, **Viveiros M**. Membrane transport systems and the biodegradation potential and pathogenicity of genus *Rhodococcus*. *Front Physiol*. 2014 Apr 4; 5:133. doi: 10.3389/fphys.2014.00133. <http://journal.frontiersin.org/Journal/10.3389/fphys.2014.00133/abstract>
23. Veigas B, Pedrosa P, Couto I, **Viveiros M**, Baptista PV. Isothermal DNA amplification coupled to Au-nanoprobes for detection of mutations associated to Rifampicin resistance in *Mycobacterium tuberculosis*. *J Nanobiotechnology*. 2013 Nov 25;11:38. doi: 10.1186/1477-3155-11-38. doi: 10.1186/1477-3155-11-38. <http://www.jnanobiotechnology.com/content/11/1/38>
24. Armada AM, Alexandru T, Machado D, Danko B, Hunyadi A, Dinache A, Nastasa V, Boni M, Ramos J, **Viveiros M**, Molnar J, Pascu ML, Amaral L. The In Vitro Activity of Products Formed from Exposure of Chlorpromazine to a 266nm LASER Beam Against Species of Mycobacteria of Human Interest. *In Vivo*. 2013 Sep-Oct;27(5):605-10. <http://iv.iijournals.org/content/27/5/605.full.pdf+html>
25. Machado D, Perdigão J, Ramos J, Couto I, Portugal I, Ritter C, Boettger EC, **Viveiros M**. High-level resistance to isoniazid and ethionamide in multidrug-resistant *Mycobacterium tuberculosis* of the Lisboa family is associated with inhA double mutations. *J Antimicrob Chemother*. 2013 Aug;68(8):1728-32. doi: 10.1093/jac/dkt090. doi: 10.1093/jac/dkt090. <http://jac.oxfordjournals.org/content/68/8/1728.full.pdf+html>
26. Costa SS, Mourato C, **Viveiros M**, Melo-Cristino J, Amaral L, Couto I. Description of plasmid pSM52, harbouring the gene for the Smr efflux pump, and its involvement in resistance to biocides in a meticillin-resistant *Staphylococcus aureus* strain. *Int J Antimicrob Agents*. 2013 May;41(5):490-2. doi: 10.1016/j.ijantimicag.2013.01.003. Epub 2013 Feb 21. doi: 10.1016/j.ijantimicag.2013.01.003. <http://www.sciencedirect.com/science/article/pii/S0924857913000307>
27. Simons SO, Kristiansen JE, Hajos G, van der Laan T, Molnár J, Boeree MJ, van Ingen J, Christensen JB, **Viveiros M**, Riedl Z, Amaral L, van Soolingen D. Activity of the efflux pump inhibitor SILA 421 against drug-resistant tuberculosis. *Int J Antimicrob Agents*. 2013 1(5):488-9. doi: 10.1016/j.ijantimicag.2013.01.001. <http://www.sciencedirect.com/science/article/pii/S0924857913000241>
28. Martins M, McCusker MP, **Viveiros M**, Couto I, Fanning S, Pagès JM, Amaral L. A Simple Method for Assessment of MDR Bacteria for Over-Expressed Efflux Pumps. *Open Microbiol J*. 2013 Mar 22;7:72-82. doi: 10.2174/1874285801307010072. <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3624690/pdf/TOMICROJ-7-72.pdf>
29. Rodrigues L, Villellas C, Bailo R, **Viveiros M**, Ainsa JA. Role of the Mmr Efflux Pump in Drug Resistance in *Mycobacterium tuberculosis*. *Antimicrob Agents Chemother*. 2013 Feb;57(2):751-7. doi: 10.1128/AAC.01482-12. <http://aac.asm.org/content/57/2/751.long>

30. Costa SS, Junqueira E, Palma C, **Viveiros M**, Melo-Cristino J, Amaral L, Couto I. Resistance to Antimicrobials Mediated by Efflux Pumps in *Staphylococcus aureus*. *Antibiotics*. 2013; 2(1):83-99. doi:10.3390/antibiotics2010083. <http://www.mdpi.com/2079-6382/2/1/83>
31. Perdigão J, Macedo R, Silva C, Machado D, Couto I, **Viveiros M**, Jordao L, Portugal I. From multidrug-resistant to extensively drug-resistant tuberculosis in Lisbon, Portugal: the stepwise mode of resistance acquisition. *J Antimicrob Chemother*. 2013 Jan;68(1):27-33. doi: 10.1093/jac/dks371. <http://jac.oxfordjournals.org/content/68/1/27.long>
32. Costa SS, **Viveiros M**, Amaral L, Couto I. Multidrug Efflux Pumps in *Staphylococcus aureus*: an Update. *Open Microbiol J*. 2013;7:59-71. Epub 2013 Mar 22. doi: 10.2174/1874285801307010059. <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3617543/pdf/TOMICROJ-7-59.pdf>
33. Costa P, Ferreira AS, Amaro A, Albuquerque T, Botelho A, Couto I, Cunha MV, **Viveiros M**, Inácio J. Enhanced detection of tuberculous mycobacteria in animal tissues using a semi-nested probe-based real-time PCR. *PLoS One*. 2013 Nov 21;8(11):e81337. doi: 10.1371/journal.pone.0081337. <http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0081337>
34. Veigas B, Jacob JM, Costa MN, Santos DS, **Viveiros M**, Inácio J, Martins R, Barquinha P, Fortunato E, Baptista PV. Gold on paper-paper platform for Au-nanoprobe TB detection. *Lab Chip*. 2012 Nov 21;12(22):4802-8. doi: 10.1039/c2lc40739f. <http://pubs.rsc.org/en/Content/ArticleLanding/2012/LC/c2lc40739f>
35. **Viveiros M**, Martins M, Rodrigues L, Machado D, Couto I, Ainsa J, Amaral L. Inhibitors of mycobacterial efflux pumps as potential boosters for anti-tubercular drugs. *Expert Rev Anti Infect Ther*. 2012 Sep;10(9):983-98. doi: 10.1586/eri.12.89. http://www.expert-reviews.com/doi/abs/10.1586/eri.12.89?url_ver=Z39.88-2003&rft_id=ori:rid:crossref.org&rft_dat=cr_pub%3dpubmed&
36. Rodrigues L, Machado D, Couto I, Amaral L, **Viveiros M**. Contribution of efflux activity to isoniazid resistance in the *Mycobacterium tuberculosis* complex. *Infect Genet Evol*. 2012 Jun;12(4):695-700. doi: 10.1016/j.meegid.2011.08.009. <http://www.sciencedirect.com/science/article/pii/S1567134811002887>
37. Amaral L, **Viveiros M**. Why thioridazine in combination with antibiotics cures extensively drug-resistant *Mycobacterium tuberculosis* infections. *Int J Antimicrob Agents*. 2012 May;39(5):376-80. doi: 10.1016/j.ijantimicag.2012.01.012. <http://www.ijaaonline.com/article/S0924-8579%2812%2900053-2/abstract>
38. Dymek A, Armada A, Handzlik J, **Viveiros M**, Spengler G, Molnar J, Kieć-Kononowicz K, Amaral L. The activity of 16 new hydantoin compounds on the intrinsic and overexpressed efflux pump system of *Staphylococcus aureus*. *In Vivo*. 2012 Mar-Apr;26(2):223-9. <http://iv.iijournals.org/content/26/2/223.long>
39. Spengler G, Rodrigues L, Martins A, Martins M, McCusker M, Cerca P, Machado L, Costa SS, Ntokou E, Couto I, **Viveiros M**, Fanning S, Molnar J, Amaral L. Genetic response of *Salmonella enterica* serotype Enteritidis to thioridazine rendering the organism resistant to the agent. *Int J Antimicrob Agents*. 2012 Jan;39(1):16-21. doi: 10.1016/j.ijantimicag.2011.08.013. <http://www.sciencedirect.com/science/article/pii/S092485791100358X>

40. Machado D, Couto I, Perdigão J, Rodrigues L, Portugal I, Baptista P, Veigas B., Amaral L., **Viveiros M.** Contribution of efflux to the emergence of isoniazid and multidrug resistance in *Mycobacterium tuberculosis*. *PLoS One*. 2012;7(4):e34538. doi: 10.1371/journal.pone.0034538.
<http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3321020/>
41. Spengler G, Molnar J, **Viveiros M**, Amaral L. Thioridazine induces apoptosis of multidrug-resistant mouse lymphoma cells transfected with the human ABCB1 and inhibits the expression of P-glycoprotein. *Anticancer Res*. 2011 Dec;31(12):4201-5.
<http://ar.iijournals.org/content/31/12/4201.long>
42. Costa SS, Falcão C, **Viveiros M**, Machado D, Martins M, Melo-Cristino J, Amaral L, Couto I. Exploring the contribution of efflux on the resistance to fluoroquinolones in clinical isolates of *Staphylococcus aureus*. *BMC Microbiol*. 2011 Oct 27;11:241. doi: 10.1186/1471-2180-11-241. Erratum in: *BMC Microbiol*. 2013;13:127.
<http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3226646/>
43. Spengler G, Handzlik J, Ocsovszki I, **Viveiros M**, Kiec-Kononowicz K, Molnar J, Amaral L. Modulation of multidrug efflux pump activity by new hydantoin derivatives on colon adenocarcinoma cells without inducing apoptosis. *Anticancer Res*. 2011 Oct;31(10):3285-8.
<http://ar.iijournals.org/content/31/10/3285.long>
44. Machado L, Spengler G, Evaristo M, Handzlik J, Molnár J, **Viveiros M**, Kiec-Kononowicz K, Amaral L. Biological activity of twenty-three hydantoin derivatives on intrinsic efflux pump system of *Salmonella enterica* serovar Enteritidis NCTC 13349. *In Vivo*. 2011 Sep-Oct;25(5):769-72.
<http://iv.iijournals.org/content/25/5/769.long>
45. Takács D, Cerca P, Martins A, Riedl Z, Hajós G, Molnár J, **Viveiros M**, Couto I, Amaral L. Evaluation of forty new phenothiazine derivatives for activity against intrinsic efflux pump systems of reference *Escherichia coli*, *Salmonella Enteritidis*, *Enterococcus faecalis* and *Staphylococcus aureus* strains. *In Vivo*. 2011 Sep-Oct;25(5):719-24.
<http://iv.iijournals.org/content/25/5/719.long>
46. Amaral L, Cerca P, Spengler G, Machado L, Martins A, Couto I, **Viveiros M**, Fanning S, Pagès JM. Ethidium bromide efflux by *Salmonella*: modulation by metabolic energy, pH, ions and phenothiazines. *Int J Antimicrob Agents*. 2011 Aug;38(2):140-5. doi: 10.1016/j.ijantimicag.2011.03.014.
<http://www.sciencedirect.com/science/article/pii/S0924857911001701>
47. Cerca P, Martins A, Couto I, **Viveiros M**, Amaral L. Competition between substrates of the efflux pump system of *Salmonella enteritidis*. *In Vivo*. 2011 Jul-Aug;25(4):597-602.
<http://iv.iijournals.org/content/25/4/597.long>
48. Amaral, L., Martins M., **Viveiros, M.** Thioridazine: Alternative and Potentially Effective Therapy of the XDR-TB Patient. *Letters in Drug Design & Discovery* 2011 8(2): 130-132.
<http://www.eurekaselect.com/87327/article>
49. Martins A, Machado L, Costa S, Cerca P, Spengler G, **Viveiros M**, Amaral L. Role of calcium in the efflux system of *Escherichia coli*. *Int J Antimicrob Agents*. 2011 May;37(5):410-4. doi: 10.1016/j.ijantimicag.2011.01.010.
<http://www.sciencedirect.com/science/article/pii/S0924857911000598>
50. Martins A, Vasas A, **Viveiros M**, Molnár J, Hohmann J, Amaral L. Antibacterial properties of compounds isolated from *Carpobrotus edulis*. *Int J Antimicrob Agents*. 2011 May;37(5):438-44. doi: 10.1016/j.ijantimicag.2011.01.016.
<http://www.sciencedirect.com/science/article/pii/S0924857911000707>

51. Amaral L, **Viveiros M**, Molnar J, Kristiansen JE. Effective Therapy with the Neuroleptic Thioridazine as an Adjunct to Second Line of Defence Drugs, and the Potential that Thioridazine Offers for New Patents that Cover a Variety of "New Uses". *Recent Pat Antiinfect Drug Discov*. 2011 May;6(2):84-7. doi: 10.2174/157489111796064542.
<http://www.eurekaselect.com/88264/article>
52. Rodrigues L, Aínsa JA, Amaral L, **Viveiros M**. Inhibition of Drug Efflux in Mycobacteria with Phenothiazines and Other Putative Efflux Inhibitors. *Recent Pat Antiinfect Drug Discov*. 2011 May;6(2):118-27. doi: 10.2174/157489111796064579
<http://www.eurekaselect.com/88270/article>
53. Pascu ML, Nastasa V, Smarandache A, Militaru A, Martins A, **Viveiros M**, Boni M, Andrei IR, Pascu A, Staicu A, Molnar J, Fanning S, Amaral L. Direct Modification of Bioactive Phenothiazines by Exposure to Laser Radiation. *Recent Pat Antiinfect Drug Discov*. 2011 May;6(2):147-57. doi: 10.2174/157489111796064542.
<http://www.eurekaselect.com/88273/article>
54. Martins M, **Viveiros M**, Couto I, Costa SS, Pacheco T, Fanning S, Pagès JM, Amaral L. Identification of efflux pump-mediated multidrug-resistant bacteria by the ethidium bromide-agar cartwheel method. *In Vivo*. 2011 Mar-Apr;25(2):171-8.
<http://iv.iarjournals.org/content/25/2/171.long>
55. Rodrigues L, Ramos J, Couto I, Amaral L, **Viveiros M**. Ethidium bromide transport across *Mycobacterium smegmatis* cell-wall: correlation with antibiotic resistance. *BMC Microbiol*. 2011 Feb 18;11:35. doi: 10.1186/1471-2180-11-35.
<http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3051877/>
56. Ramalhete C, Spengler G, Martins A, Martins M, **Viveiros M**, Mulhovo S, Ferreira MJ, Amaral L. Inhibition of efflux pumps in methicillin-resistant *Staphylococcus aureus* and *Enterococcus faecalis* resistant strains by triterpenoids from *Momordica balsamina*. *Int J Antimicrob Agents*. 2011 Jan;37(1):70-4. doi: 10.1016/j.ijantimicag.2010.09.011.
<http://www.sciencedirect.com/science/article/pii/S0924857910004346>
57. Spengler G, Evaristo M, Handzlik J, Serly J, Molnár J, **Viveiros M**, Kiéc-Kononowicz K, Amaral L. Biological activity of hydantoin derivatives on P-glycoprotein (ABCB1) of mouse lymphoma cells. *Anticancer Res*. 2010 Dec;30(12):4867-71.
<http://ar.iarjournals.org/content/30/12/4867.long>
58. Costa SS, Ntokou E, Martins A, **Viveiros M**, Pournaras S, Couto I, Amaral L. Identification of the plasmid-encoded *qacA* efflux pump gene in methicillin-resistant *Staphylococcus aureus* (MRSA) strain HPV107, a representative of the MRSA Iberian clone. *Int J Antimicrob Agents*. 2010 Dec;36(6):557-61. doi: 10.1016/j.ijantimicag.2010.08.006.
<http://www.sciencedirect.com/science/article/pii/S0924857910003559>
59. Veigas B, Machado D, Perdigão J, Portugal I, Couto I, **Viveiros M**, Baptista PV. Au-nanoprobes for detection of SNPs associated with antibiotic resistance in *Mycobacterium tuberculosis*. *Nanotechnology*. 2010 Oct 15;21(41):415101. doi: 10.1088/0957-4484/21/41/415101.
<http://iopscience.iop.org/0957-4484/21/41/415101/>
60. Martins A, Spengler G, Martins M, Rodrigues L, **Viveiros M**, Davin-Regli A, Chevalier J, Couto I, Pagès JM, Amaral L. Physiological characterisation of the efflux pump system of antibiotic-susceptible and multidrug-resistant *Enterobacter aerogenes*. *Int J Antimicrob Agents*. 2010 Oct;36(4):313-8. doi: 10.1016/j.ijantimicag.2010.06.036.
<http://www.sciencedirect.com/science/article/pii/S0924857910002943>

61. Kristiansen JE, Thomsen VF, Martins A, **Viveiros M**, Amaral L. Non-antibiotics reverse resistance of bacteria to antibiotics. *In Vivo*. 2010 Sep-Oct;24(5):751-4.
<http://iv.iarjournals.org/content/24/5/751.long>
62. Couto I, Machado D, **Viveiros M**, Rodrigues L, Amaral L. Identification of nontuberculous mycobacteria in clinical samples using molecular methods: a 3-year study. *Clin Microbiol Infect*. 2010 Aug;16(8):1161-4. doi: 10.1111/j.1469-0691.2009.03076.x.
<http://onlinelibrary.wiley.com/doi/10.1111/j.1469-0691.2009.03076.x/abstract>
63. Chevalier J, Mahamoud A, Baitiche M, Adam E, **Viveiros M**, Smarandache A, Militaru A, Pascu ML, Amaral L, Pagès JM. Quinazoline derivatives are efficient chemosensitizers of antibiotic activity in *Enterobacter aerogenes*, *Klebsiella pneumoniae* and *Pseudomonas aeruginosa* resistant strains. *Int J Antimicrob Agents*. 2010 Aug;36(2):164-8. doi: 10.1016/j.ijantimicag.2010.03.027.
<http://www.sciencedirect.com/science/article/pii/S0924857910001615>
64. Amaral L, Martins A, Molnar J, Kristiansen JE, Martins M, **Viveiros M**, Rodrigues L, Spengler G, Couto I, Ramos J, Dastidar S, Fanning S, McCusker M, Pages JM. Phenothiazines, bacterial efflux pumps and targeting the macrophage for enhanced killing of intracellular XDRTB. *In Vivo*. 2010 Jul-Aug;24(4):409-24.
<http://iv.iarjournals.org/content/24/4/409.long>
65. **Viveiros M**, Martins M, Couto I, Rodrigues L, Machado D, Portugal I, Amaral L. Molecular tools for rapid identification and novel effective therapy against MDRTB/XDRTB infections. *Expert Rev Anti Infect Ther*. 2010 Apr;8(4):465-80. doi: 10.1586/eri.10.20.
http://www.expert-reviews.com/doi/abs/10.1586/eri.10.20?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed&
66. Martins A, Vasas A, Schelz Z, **Viveiros M**, Molnár J, Hohmann J, Amaral L. Constituents of *Carpobrotus edulis* inhibit P-glycoprotein of MDR1-transfected mouse lymphoma cells. *Anticancer Res*. 2010 Mar;30(3):829-35.
<http://ar.iarjournals.org/content/30/3/829.long>
67. **Viveiros M**, Rodrigues L, Martins M, Couto I, Spengler G, Martins A, Amaral L. Evaluation of efflux activity of bacteria by a semi-automated fluorometric system. *Methods Mol Biol*. 2010;642:159-72. doi: 10.1007/978-1-60327-279-7_12.
http://link.springer.com/protocol/10.1007%2F978-1-60327-279-7_12
68. Martins M, Couto I, **Viveiros M**, Amaral L. Identification of efflux-mediated multi-drug resistance in bacterial clinical isolates by two simple methods. *Methods Mol Biol*. 2010;642:143-57. doi: 10.1007/978-1-60327-279-7_11.
http://link.springer.com/protocol/10.1007%2F978-1-60327-279-7_11
69. Rodrigues L, Sampaio D, Couto I, Machado D, Kern WV, Amaral L, **Viveiros M**. The role of efflux pumps in macrolide resistance in *Mycobacterium avium* complex. *Int J Antimicrob Agents*. 2009 Dec;34(6):529-33. doi: 10.1016/j.ijantimicag.2009.07.010.
<http://www.sciencedirect.com/science/article/pii/S0924857909003653>
70. Martins A, Iversen C, Rodrigues L, Spengler G, Ramos J, Kern WV, Couto I, **Viveiros M**, Fanning S, Pages JM, Amaral L. An AcrAB-mediated multidrug-resistant phenotype is maintained following restoration of wild-type activities by efflux pump genes and their regulators. *Int J Antimicrob Agents*. 2009 Dec;34(6):602-4. doi: 10.1016/j.ijantimicag.2009.06.029.
<http://www.sciencedirect.com/science/article/pii/S0924857909003549>

71. Paixão L, Rodrigues L, Couto I, Martins M, Fernandes P, de Carvalho CC, Monteiro GA, Sansonetty F, Amaral L, **Viveiros M**. Fluorometric determination of ethidium bromide efflux kinetics in *Escherichia coli*. *J Biol Eng*. 2009 Oct 16;3:18. doi: 10.1186/1754-1611-3-18.
<http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2774284/>
72. Spengler G, Ramalheite C, Martins M, Martins A, Serly J, **Viveiros M**, Molnár J, Duarte N, Mulhovo S, Ferreira MJ, Amaral L. Evaluation of cucurbitane-type triterpenoids from *Momordica balsamina* on P-glycoprotein (ABCB1) by flow cytometry and real-time fluorometry. *Anticancer Res*. 2009 Oct;29(10):3989-93.
<http://ar.iijournals.org/content/29/10/3989.long>
73. Martins A, Spengler G, Rodrigues L, **Viveiros M**, Ramos J, Martins M, Couto I, Fanning S, Pagès JM, Bolla JM, Molnar J, Amaral L. pH Modulation of efflux pump activity of multi-drug resistant *Escherichia coli*: protection during its passage and eventual colonization of the colon. *PLoS One*. 2009 Aug 17;4(8):e6656. doi: 10.1371/journal.pone.0006656.
<http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722724/>
74. Spengler G, **Viveiros M**, Martins M, Rodrigues L, Martins A, Molnar J, Couto I, Amaral L. Demonstration of the activity of P-glycoprotein by a semi-automated fluorometric method. *Anticancer Res*. 2009 Jun;29(6):2173-7.
<http://ar.iijournals.org/content/29/6/2173.long>
75. Martins M, **Viveiros M**, Ramos J, Couto I, Molnar J, Boeree M, Amaral L. SILA 421, an inhibitor of efflux pumps of cancer cells, enhances the killing of intracellular extensively drug-resistant tuberculosis (XDR-TB). *Int J Antimicrob Agents*. 2009 May;33(5):479-82. doi: 10.1016/j.ijantimicag.2008.10.028.
<http://www.sciencedirect.com/science/article/pii/S0924857908005724>
76. Martins M, **Viveiros M**, Couto I, Amaral L. Targeting human macrophages for enhanced killing of intracellular XDR-TB and MDR-TB. *Int J Tuberc Lung Dis*. 2009 May;13(5):569-73.
<http://www.ingentaconnect.com/content/iuatld/ijitld/2009/00000013/00000005/art00008?token=005113dc8dc67232d45232b5f247a6a2d574766737a283568293c62207d673f582f6b0130dc334589>
77. Spengler G, Martins A, Schelz Z, Rodrigues L, Aagaard L, Martins M, Costa SS, Couto I, **Viveiros M**, Fanning S, Kristiansen JE, Molnar J, Amaral L. Characterization of intrinsic efflux activity of *Enterococcus faecalis* ATCC29212 by a semi-automated ethidium bromide method. *In Vivo*. 2009 Jan-Feb;23(1):81-7.
<http://iv.iijournals.org/content/23/1/81.long>
78. Amaral L, Martins M, **Viveiros M**, Molnar J, Kristiansen JE. Promising therapy of XDR-TB/MDR-TB with thioridazine an inhibitor of bacterial efflux pumps. *Curr Drug Targets*. 2008 Sep;9(9):816-9. doi: 10.2174/138945008785747798.
<http://www.eurekaselect.com/67599/article>
79. **Viveiros M**, Martins M, Couto I, Rodrigues L, Spengler G, Martins A, Kristiansen JE, Molnar J, Amaral L. New methods for the identification of efflux mediated MDR bacteria, genetic assessment of regulators and efflux pump constituents, characterization of efflux systems and screening for inhibitors of efflux pumps. *Curr Drug Targets*. 2008 Sep;9(9):760-78. doi: 10.2174/138945008785747734
<http://www.eurekaselect.com/67594/article>
80. Couto I, Costa SS, **Viveiros M**, Martins M, Amaral L. Efflux-mediated response of *Staphylococcus aureus* exposed to ethidium bromide. *J Antimicrob Chemother*. 2008 Sep;62(3):504-13. doi: 10.1093/jac/dkn217.
<http://jac.oxfordjournals.org/content/62/3/504.long>

81. **Viveiros M**, Martins A, Paixão L, Rodrigues L, Martins M, Couto I, Fähnrich E, Kern WV, Amaral L. Demonstration of intrinsic efflux activity of *Escherichia coli* K-12 AG100 by an automated ethidium bromide method. *Int J Antimicrob Agents*. 2008 May;31(5):458-62. doi: 10.1016/j.ijantimicag.2007.12.015.
<http://www.sciencedirect.com/science/article/pii/S0924857908000320>
82. Rodrigues L, Wagner D, **Viveiros M**, Sampaio D, Couto I, Vavra M, Kern WV, Amaral L. Thioridazine and chlorpromazine inhibition of ethidium bromide efflux in *Mycobacterium avium* and *Mycobacterium smegmatis*. *J Antimicrob Chemother*. 2008 May;61(5):1076-82. doi: 10.1093/jac/dkn070.
<http://jac.oxfordjournals.org/content/61/5/1076.long>
83. Martins M, **Viveiros M**, Amaral L. The TB laboratory of the future: macrophage-based selection of XDR-TB therapeutics. *Future Microbiol*. 2008 Apr;3:135-44. doi: 10.2217/17460913.3.2.135.
http://www.futuremedicine.com/doi/abs/10.2217/17460913.3.2.135?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed&
84. Martins M, Dastidar SG, Fanning S, Kristiansen JE, Molnar J, Pagès JM, Schelz Z, Spengler G, **Viveiros M**, Amaral L. Potential role of non-antibiotics (helper compounds) in the treatment of multidrug-resistant Gram-negative infections: mechanisms for their direct and indirect activities. *Int J Antimicrob Agents*. 2008 Mar;31(3):198-208. doi: 10.1016/j.ijantimicag.2007.10.025.
<http://www.sciencedirect.com/science/article/pii/S0924857907005572>
85. Martins M, **Viveiros M**, Amaral L. Inhibitors of Ca²⁺ and K⁺ transport enhance intracellular killing of *M. tuberculosis* by non-killing macrophages. *In Vivo*. 2008 Jan-Feb;22(1):69-75.
<http://iv.iijournals.org/content/22/1/69.long>
86. Martins M, **Viveiros M**, Kristiansen JE, Molnar J, Amaral L. The curative activity of thioridazine on mice infected with *Mycobacterium tuberculosis*. *In Vivo*. 2007 Sep-Oct;21(5):771-5.
<http://iv.iijournals.org/content/21/5/771.long>
87. Amaral L, Martins M, **Viveiros M**. Phenothiazines as anti-multi-drug resistant tubercular agents. *Infect Disord Drug Targets*. 2007 Sep;7(3):257-65. doi: 10.2174/187152607782110022
<http://www.eurekaselect.com/78873/article>
88. Schelz Z, Martins M, Martins A, **Viveiros M**, Molnar J, Amaral L. Elimination of plasmids by SILA compounds that inhibit efflux pumps of bacteria and cancer cells. *In Vivo*. 2007 Jul-Aug;21(4):635-9.
<http://iv.iijournals.org/content/21/4/635.long>
89. Duarte N, Ferreira MJ, Martins M, **Viveiros M**, Amaral L. Antibacterial activity of ergosterol peroxide against *Mycobacterium tuberculosis*: dependence upon system and medium employed. *Phytother Res*. 2007 Jul;21(7):601-4. doi: 10.1002/ptr.2119.
<http://onlinelibrary.wiley.com/doi/10.1002/ptr.2119/abstract;jsessionid=44FB2432A6DF4040AEEBEEA16502FFC3.d04t04>
90. Amaral L, Martins M, **Viveiros M**. Enhanced killing of intracellular multidrug-resistant *Mycobacterium tuberculosis* by compounds that affect the activity of efflux pumps. *J Antimicrob Chemother*. 2007 Jun;59(6):1237-46. doi: 10.1093/jac/dkl500.
<http://jac.oxfordjournals.org/content/59/6/1237.long>

91. **Viveiros M**, Dupont M, Rodrigues L, Couto I, Davin-Regli A, Martins M, Pagès JM, Amaral L. Antibiotic stress, genetic response and altered permeability of *Escherichia coli*. *PLoS One*. 2007 Apr 11;2(4):e365. doi: 10.1371/journal.pone.0000365.
<http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1838523/>
92. Amaral L, Engi H, Viveiros M, Molnar J. Review. Comparison of multidrug resistant efflux pumps of cancer and bacterial cells with respect to the same inhibitory agents. *In Vivo*. 2007 Mar-Apr;21(2):237-44.
<http://iv.iijournals.org/content/21/2/237.long>
93. Martins A, Couto I, Aagaard L, Martins M, **Viveiros M**, Kristiansen JE, Amaral L. Prolonged exposure of methicillin-resistant *Staphylococcus aureus* (MRSA) COL strain to increasing concentrations of oxacillin results in a multidrug-resistant phenotype. *Int J Antimicrob Agents*. 2007 Mar;29(3):302-5. Epub 2007 Feb 2. doi:10.1016/j.ijantimicag.2006.10.012.
<http://www.sciencedirect.com/science/article/pii/S0924857906004730>
94. Martins M, Schelz Z, Martins A, Molnar J, Hajös G, Riedl Z, **Viveiros M**, Yalcin I, Aki-Sener E, Amaral L. In vitro and ex vivo activity of thioridazine derivatives against *Mycobacterium tuberculosis*. *Int J Antimicrob Agents*. 2007 Mar;29(3):338-40. doi:10.1016/j.ijantimicag.2006.10.013.
<http://www.sciencedirect.com/science/article/pii/S0924857906004742>
95. Martins M, Santos B, Martins A, **Viveiros M**, Couto I, Cruz A, Pagès JM, Molnar J, Fanning S, Amaral L Management Committee Members; of Cost B16; European Commission/European Science Foundation. An instrument-free method for the demonstration of efflux pump activity of bacteria. *In Vivo*. 2006 Sep-Oct;20(5):657-64.
<http://iv.iijournals.org/content/20/5/657.long>
96. Martins M., **Viveiros M.**, Ordway D., Kristiansen J.E., Molnár J. and Amaral L. Reserpine, Ouabain and the Calcium Channel Blocker Verapamil, cause intracellular killing of *Staphylococcus aureus*. *Research Journal of Microbiology*. 2006 1(3):203-209. doi: jm.2006.203.209.
<http://scialert.net/qredirect.php?doi=jm.2006.203.209&linkid=pdf>
97. Amaral L, **Viveiros M**, Kristiansen JE. "Non-Antibiotics": alternative therapy for the management of MDRTB and MRSA in economically disadvantaged countries. *Curr Drug Targets*. 2006 Jul;7(7):887-91. doi: 10.2174/138945006777709539.
<http://www.eurekaselect.com/56303/article>
98. Wolfart K, Spengler G, Kawase M, Motohashi N, Molnár J, **Viveiros M**, Amaral L. Synergistic interaction between proton pump inhibitors and resistance modifiers: promoting effects of antibiotics and plasmid curing. *In Vivo*. 2006 May-Jun;20(3):367-72.
<http://iv.iijournals.org/content/20/3/367.long>
99. Kristiansen MM, Leandro C, Ordway D, Martins M, **Viveiros M**, Pacheco T, Molnar J, Kristiansen JE, Amaral L. Thioridazine reduces resistance of methicillin-resistant *Staphylococcus aureus* by inhibiting a reserpine-sensitive efflux pump. *In Vivo*. 2006 May-Jun;20(3):361-6.
<http://iv.iijournals.org/content/20/3/361.long>
100. Ordway D. J., **Viveiros M.**, Ventura F. A., Orme I. M., Dockrell H. M. and Amaral L. Exogenous re-infection by multiple exposures to *Mycobacterium tuberculosis* contributes to subsequent development of active tuberculosis. *American Journal of Immunology* 2005 1(1): 42-47. doi: 10.3844/ajisp.2005.42.47
<http://thescipub.com/abstract/10.3844/ajisp.2005.42.47>

101. **Viveiros M**, Leandro C, Rodrigues L, Almeida J, Bettencourt R, Couto I, Carrilho L, Diogo J, Fonseca A, Lito L, Lopes J, Pacheco T, Pessanha M, Quirim J, Sancho L, Salfinger M, Amaral L. Direct application of the INNO-LiPA Rif.TB line-probe assay for rapid identification of *Mycobacterium tuberculosis* complex strains and detection of rifampin resistance in 360 smear-positive respiratory specimens from an area of high incidence of multidrug-resistant tuberculosis. *J Clin Microbiol*. 2005 Sep;43(9):4880-4. doi: 10.1128/JCM.43.9.4880-4884.2005.
<http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1234138/>
102. **Viveiros M**, Jesus A, Brito M, Leandro C, Martins M, Ordway D, Molnar AM, Molnar J, Amaral L. Inducement and reversal of tetracycline resistance in *Escherichia coli* K-12 and expression of proton gradient-dependent multidrug efflux pump genes. *Antimicrob Agents Chemother*. 2005 Aug;49(8):3578-82. doi: 10.1128/AAC.49.8.3578-3582.2005.
<http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1196278/>
103. **Viveiros M**, Martins M, Couto I, Kristiansen JE, Molnar J, Amaral L. The in vitro activity of phenothiazines against *Mycobacterium avium*: potential of thioridazine for therapy of the co-infected AIDS patient. *In Vivo*. 2005 Jul-Aug;19(4):733-6.
<http://iv.iijournals.org/content/19/4/733>
104. Ordway DJ, Pinto L, Costa L, Martins M, Leandro C, **Viveiros M**, Amaral L, Arroiz MJ, Ventura FA, Dockrell HM. Gamma delta T cell responses associated with the development of tuberculosis in health care workers. *FEMS Immunol Med Microbiol*. 2005 Mar 1;43(3):339-50. doi: 10.1016/j.femsim.2004.09.005.
<http://onlinelibrary.wiley.com/doi/10.1016/j.femsim.2004.09.005/abstract>
105. Martins M, Ordway D, Kristiansen M, **Viveiros M**, Leandro C, Molnar J, Amaral L. Inhibition of the *Carpobrotus edulis* methanol extract on the growth of phagocytosed multidrug-resistant *Mycobacterium tuberculosis* and methicillin-resistant *Staphylococcus aureus*. *Fitoterapia*. 2005 Jan;76(1):96-9. doi:10.1016/j.fitote.2004.09.020.
<http://www.sciencedirect.com/science/article/pii/S0367326X0400228X>
106. Martins M, Bleiss W, Marko A, Ordway D, **Viveiros M**, Leandro C, Pacheco T, Molnar J, Kristiansen JE, Amaral L. Clinical concentrations of thioridazine enhance the killing of intracellular methicillin-resistant *Staphylococcus aureus*: an in vivo, ex vivo and electron microscopy study. *In Vivo*. 2004 Nov-Dec;18(6):787-94.
<http://iv.iijournals.org/content/18/6/787>
107. Amaral L, **Viveiros M**, Molnar J. Antimicrobial activity of phenothiazines. *In Vivo*. 2004 Nov-Dec;18(6):725-31.
<http://iv.iijournals.org/content/18/6/725>
108. Grácio MA, Grácio AJ, **Viveiros M**, Amaral L. Since phenothiazines alter antibiotic susceptibility of microorganisms by inhibiting efflux pumps, are these agents useful for evaluating similar pumps in phenothiazine-sensitive parasites? *Int J Antimicrob Agents*. 2003 Sep;22(3):347-51. doi:10.1016/S0924-8579(03)00204-8.
<http://www.sciencedirect.com/science/article/pii/S0924857903002048>
109. **Viveiros M**, Leandro C, Amaral L. Mycobacterial efflux pumps and chemotherapeutic implications. *Int J Antimicrob Agents*. 2003 Sep;22(3):274-8. doi:10.1016/S0924-8579(03)00208-5.
<http://www.sciencedirect.com/science/article/pii/S0924857903002085>
110. Kristiansen MM, Leandro C, Ordway D, Martins M, **Viveiros M**, Pacheco T, Kristiansen JE, Amaral L. Phenothiazines alter resistance of methicillin-resistant strains of *Staphylococcus aureus* (MRSA) to oxacillin in vitro. *Int J Antimicrob Agents*. 2003 Sep;22(3):250-3. doi:10.1016/S0924-8579(03)00200-0.
<http://www.sciencedirect.com/science/article/pii/S0924857903002000>

111. Ordway D, Hohmann J, **Viveiros M**, Viveiros A, Molnar J, Leandro C, Arroz MJ, Gracio MA, Amaral L. Carpobrotus edulis methanol extract inhibits the MDR efflux pumps, enhances killing of phagocytosed *S. aureus* and promotes immune modulation. *Phytother Res*. 2003 May;17(5):512-9. doi: 10.1002/ptr.1314.
<http://onlinelibrary.wiley.com/doi/10.1002/ptr.1314/abstract>
112. Ordway D, **Viveiros M**, Leandro C, Bettencourt R, Almeida J, Martins M, Kristiansen JE, Molnar J, Amaral L. Clinical concentrations of thioridazine kill intracellular multidrug-resistant *Mycobacterium tuberculosis*. *Antimicrob Agents Chemother*. 2003 Mar;47(3):917-22. doi: 10.1128/AAC.47.3.917-922.2003.
<http://www.ncbi.nlm.nih.gov/pmc/articles/PMC149316/>
113. **Viveiros M**, Portugal I, Bettencourt R, Victor TC, Jordaan AM, Leandro C, Ordway D, Amaral L. Isoniazid-induced transient high-level resistance in *Mycobacterium tuberculosis*. *Antimicrob Agents Chemother*. 2002 Sep;46(9):2804-10. doi: 10.1128/AAC.46.9.2804-2810.2002.
<http://www.ncbi.nlm.nih.gov/pmc/articles/PMC127392/>
114. Ordway D, **Viveiros M**, Leandro C, Jorge Arroz M, Molnar J, Kristiansen JE, Amaral L. Chlorpromazine has intracellular killing activity against phagocytosed *Staphylococcus aureus* at clinical concentrations. *J Infect Chemother*. 2002 Sep;8(3):227-31.
<http://link.springer.com/article/10.1007/s10156-002-0188-4>
115. Ordway D, **Viveiros M**, Leandro C, Arroz MJ, Amaral L. Intracellular activity of clinical concentrations of phenothiazines including thioridazine against phagocytosed *Staphylococcus aureus*. *Int J Antimicrob Agents*. 2002 Jul;20(1):34-43. doi:10.1016/S0924-8579(02)00110-3
<http://www.sciencedirect.com/science/article/pii/S0924857902001103>
116. Amaral L, **Viveiros M**, Kristiansen JE. Phenothiazines: potential alternatives for the management of antibiotic resistant infections of tuberculosis and malaria in developing countries. *Trop Med Int Health*. 2001 Dec;6(12):1016-22. doi: 10.1046/j.1365-3156.2001.00804.x
<http://onlinelibrary.wiley.com/doi/10.1046/j.1365-3156.2001.00804.x/abstract;jsessionid=4DA2BBC8BBB68AFB65EEA6DD1AF71962.d04t04>
117. Amaral L, Kristiansen JE, **Viveiros M**, Atouguia J. Activity of phenothiazines against antibiotic-resistant *Mycobacterium tuberculosis*: a review supporting further studies that may elucidate the potential use of thioridazine as anti-tuberculosis therapy. *J Antimicrob Chemother*. 2001 May;47(5):505-11. doi: 10.1093/jac/47.5.505.
<http://jac.oxfordjournals.org/content/47/5/505.long>
118. **Viveiros M**, Amaral L. Enhancement of antibiotic activity against poly-drug resistant *Mycobacterium tuberculosis* by phenothiazines. *Int J Antimicrob Agents*. 2001 Mar;17(3):225-8. doi:10.1016/S0924-8579(00)00343-5.
<http://www.sciencedirect.com/science/article/pii/S0924857900003435>
119. **Viveiros-Bettencourt M**, Bosne-David S, Amaral L. Comparative in vitro activity of phenothiazines against multidrug-resistant *Mycobacterium tuberculosis*. *Int J Antimicrob Agents*. 2000 Sep;16(1):69-71. doi:10.1016/S0924-8579(00)00199-0.
<http://www.sciencedirect.com/science/article/pii/S0924857900001990>
120. **Viveiros M**, Krubasik P, Sandmann G, Houssaini-Iraqi M. Structural and functional analysis of the gene cluster encoding carotenoid biosynthesis in *Mycobacterium aurum* A+. *FEMS Microbiol Lett*. 2000 Jun 1;187(1):95-101. doi:10.1016/S0378-1097(00)00182-8
<http://www.sciencedirect.com/science/article/pii/S0378109700001828>

121. **Viveiros M**, Pinheiro S, Moreira P, Pacheco T, Brum L. Evaluation of a commercial ligase chain reaction assay for the diagnosis of pulmonary and extra-pulmonary tuberculosis. *Int J Tuberc Lung Dis*. 1999 Jun;3(6):508-14.
<http://www.ingentaconnect.com/content/iuatld/ijtld/1999/00000003/00000006/art00009?token=005e1dff1499aaaa8229e41333c4a2f7a3f6a2d2c2046547d3f3c624f6d6222346b626876305021f35b4fecf65e4f7>
122. **Portugal I**, Covas MJ, Brum L, Viveiros M, Ferrinho P, Moniz-Pereira J, David HL. Outbreak of multiple drug-resistant tuberculosis in Lisbon: detection by restriction fragment length polymorphism analysis. *Int J Tuberc Lung Dis*. 1999 Mar;3(3):207-13.
<http://www.ingentaconnect.com/content/iuatld/ijtld/1999/00000003/00000003/art00007?token=004f1aa34d6178d2ea573d257025702c236e2f5f3172767c2b657c4e75477e4324576b6427386fa>
123. Ribeiro G, **Viveiros M**, David HL, Costa JV. Mycobacteriophage D29 contains an integration system similar to that of the temperate mycobacteriophage L5. *Microbiology*. 1997 Aug;143 (Pt 8):2701-8. doi: 10.1099/00221287-143-8-2701
<http://mic.sgmjournals.org/content/143/8/2701.long>

BOOKS AND BOOK CHAPTERS (N = 19):

1. Ordway D.J., **Viveiros M.**, Ventura F.A., Dockrell H.M. and Amaral L. (2005) Does multiple exposure to Mycobacterium tuberculosis lead to reduction of a Th1 immune response and concomitant presence of Th2 immune response which contributes to subsequent development of active tuberculosis?. In: Research Advances in Infectious Diseases, Mohan R.M. editor, Global Research Network, Kerala, India, p.15-34.
2. **Viveiros M.**, Leandro C., Rodrigues L., Almeida J., Bettencourt R., Couto I., Carrilho L., Diogo J., Fonseca A., Lito L., Lopes J., Pacheco T., Pessanha M., Quirim J., Sancho L. and Salfinger M. (2006). Diagnóstico precoce da tuberculose multirresistente (TBMR): O Programa Faster-Track de Combate à Tuberculose Multirresistente na Grande Lisboa. In: Tuberculose - Impacto da Infecção VIH. Jaime Pina editor, Sociedade Portuguesa de Pneumologia - Hospital Pulido Valente – GlaxoSmithKline, Lisboa, Portugal, p.83-99.
3. **Viveiros M.** and Atouguia J. (2008) Tuberculose – Saúde Tropical. Edição Universidade Aberta (ISBN:978-972-674-494-8) 155 pp.
<http://loja.uab.pt/scripto/textos-de-cursos-nao-formais/produto/tuberculose-1368.aspx>
4. **Viveiros M.** (2010) Segurança no Laboratório de Microbiologia In: Microbiologia (1ª Edição), Wanda F. Canas Ferreira, João Carlos F. de Sousa and Nelson Lima editores, Lidel, Edições Técnicas, Lisboa, Portugal. pp. - 588-609 (ISBN 9789727575152)
http://www.fca.pt/cgi-bin/lidel_main.cgi/?op=3&mnu=100&edicao=1&isbn=978-972-757-515-2
5. **Viveiros M.**, Rodrigues L., Martins M., Couto I., Martins A., Spengler G. and Amaral L. (2009) Evaluation of efflux activity of bacteria by an ethidium bromide semi-automated fluorometric system. In: Antibiotic Resistance Protocols for Methods in Molecular Medicine Series, Second Edition. John Walker editor. Humana Press, Springer Science+Business Media, LLC. Londres, Reino Unido. pp. 159-172. (ISBN 978-1-60327-278-0).
http://www.springerprotocols.com/Abstract/doi/10.1007/978-1-60327-279-7_12
6. Martins M., Couto I., **Viveiros M.** and Amaral L (2009) Identification of efflux- mediated multi-drug resistance in bacterial clinical isolates by two simple methods. In: Antibiotic Resistance Protocols for Methods in Molecular Medicine Series, Second Edition. John Walker editor. Humana Press, Springer Science+Business Media, LLC. Londres, Reino Unido. pp. 143-157 (ISBN 978-1-60327-278-0).
http://www.springerprotocols.com/Abstract/doi/10.1007/978-1-60327-279-7_12
7. Amaral L., Fanning S., Spengler G., Rodrigues L., Iversen C., Martins M., Martins A., **Viveiros M.** and Couto I. (2009) Genetic regulation, physiology, assessment and inhibition of efflux pumps responsible for multi-drug resistant phenotypes of bacterial pathogens (I) In: Antibiotic Resistance . 1st Edition_eBook. Agoston Meszaros and Gusztav Balogh editors. NovaScience, Nova York, EUA. (ISBN 978-1-61668-162-3).
https://www.novapublishers.com/catalog/product_info.php?products_id=12660
8. Amaral L., Fanning S., Spengler G., Rodrigues L., Iversen C., Martins M., Martins A., **Viveiros M.** and Couto I. (2011) Genetic regulation, physiology, assessment and inhibition of efflux pumps responsible for multi-drug resistant phenotypes of bacterial pathogens (II) In: Antibiotic Resistance: Causes and Risk Factors, Mechanisms and Alternatives. 2nd Edition_Hardcover. Adriel R. Bonilla and Kaden P. Muniz editors. NovaScience, Nova York, EUA. pp. 313-332. (ISBN 978-1-60741-623-4).
https://www.novapublishers.com/catalog/product_info.php?products_id=10081

9. Amaral L., Fanning S., Spengler G., Rodrigues L., Iversen C., Martins M., Martins A., **Viveiros M.** and Couto I. (2011) Genetic regulation, physiology, assessment and inhibition of efflux pumps responsible for multi-drug resistant phenotypes of bacterial pathogens (III) In: Multiple Drug Resistance. Agoston Meszaros and Gusztav Balogh editors. NovaScience, Nova York, EUA. 312 pags.. (ISBN 978-1-60741-595-4).
https://www.novapublishers.com/catalog/product_info.php?products_id=10044
10. Amaral L., Fanning S., Spengler G., Rodrigues L., Iversen C., Martins M., Martins A., **Viveiros M.** and Couto I. (2012) Genetic regulation, physiology, assessment and inhibition of efflux pumps responsible for multi-drug resistant phenotypes of bacterial pathogens (IV) In: Bacterial Pathogens: Virulence Mechanisms, Diagnosis and Management. Aimee Boulanger and Maison Blanc editors. NovaScience, Nova York, EUA. pp. 66-85. (ISBN 978-1-62081-887-9).
https://www.novapublishers.com/catalog/product_info.php?products_id=30993
11. **Viveiros M.** (2012) A Importância da Biossegurança Como Disciplina Curricular. In Workshop Biossegurança: Situação em Portugal. Sofia Nuncio, Ana Pelerito, Rita Cordeiro editors. Ministério da Saúde. Instituto Nacional de Saúde Doutor Ricardo Jorge, IP, Lisboa, Portugal. pp. 13-17. (ISBN: 978-972-8643-75-1).
<http://repositorio.insa.pt/bitstream/10400.18/1538/3/Workshop%20Biosseguran%C3%A7a%20-%20Situa%C3%A7%C3%A3o%20em%20Portugal.pdf>
12. Amaral L., Martins A., Spengler G., Martins M., McCusker M., **Viveiros M.**, Fanning S. and Molnar J. (2013) Structure, Genetic Regulation, Physiology and Function of the AcrAB-TolC Efflux Pump of *Escherichia coli* and *Salmonella*. In: Antimicrobial Drug Discovery-Emerging Strategies. George Tegos and E Mylonakis, editors. CABI Publishing, Oxfordshire, UK, pp. 44-61. (ISBN 781-84593-943-4).
<http://bookshop.cabi.org/default.aspx?site=191&page=2633&pid=2443>
13. **Viveiros M.** Machado D., Couto I. and Amaral L (2013) Improving on the LJ slope – automated liquid culture. In: Tuberculosis - Diagnosis and Treatment (Advances in Molecular and Cellular Microbiology Series) T D McHugh, editor. CABI Publishing, Oxfordshire, UK, 304 pag. (ISBN 781-84593-807-9).
<http://bookshop.cabi.org/?page=2633&pid=2372&site=191>
14. Amaral L, Martins M, Couto I, **Viveiros M** (2013) Therapy of the XDR-TB Patients with Thioridazine - an Old Drug with New Applications. In: Tuberculosis - Diagnosis and Treatment (Advances in Molecular and Cellular Microbiology Series) T D McHugh, editor. CABI Publishing, Oxfordshire, UK, 304 pag. (ISBN 781-84593-807-9).
<http://bookshop.cabi.org/?page=2633&pid=2372&site=191>
15. **Viveiros M.** Couto I and Inácio J. (2014) Diagnóstico Molecular. In: Microbiologia Médica, António Meliço-Silvestre, Helena Barroso and Nuno Taveira editores, Lidel, Edições Técnicas, Lisboa, Portugal. (ISBN - 978-972-757-576-3).
https://www.fca.pt/cgi-bin/lidel_main.cgi/?op=3&mnu=100&edicao=1&isbn=978-989-752-057-0&novidade=0
http://issuu.com/lidel/docs/microbiologia_medica_volume_1?mode=embed&layout=http%3A%2F%2Fskin.issuu.com%2Fv%2Flight%2Flayout.xml&showFlipBtn=true
16. Portugal, I. and **Viveiros M.** (2014) *Mycobacterium* In: Microbiologia Médica, António Meliço-Silvestre, Helena Barroso and Nuno Taveira editores, Lidel, Edições Técnicas, Lisboa, Portugal. (ISBN - 978-972-757-576-3).
https://www.fca.pt/cgi-bin/lidel_main.cgi/?op=3&mnu=100&edicao=1&isbn=978-989-752-057-0&novidade=0
http://issuu.com/lidel/docs/microbiologia_medica_volume_1?mode=embed&layout=http%3A%2F%2Fskin.issuu.com%2Fv%2Flight%2Flayout.xml&showFlipBtn=true

17. **Viveiros M.**, Couto I., Rossetti ML and da Silva PA (2014) Otimização, validação e controlo de qualidade de testes moleculares de diagnóstico. In: *Abordagens Moleculares em Veterinária*. Mónica V. Cunha e João Inácio editores, Lidel, Edições Técnicas, Lisboa, Portugal. (ISBN - 978-989-752-034-1).
https://www.fca.pt/cgi-bin/lidel_main.cgi/?op=3&mnu=100&edicao=1&isbn=978-989-752-034-1
<http://issuu.com/lidel/docs/abordagensmolecularesveterinaria/1>
18. Costa P., Couto I., **Viveiros M.**, and Inácio J. (2014) Nested and Multiplex Real Time PCR Using Dual-Labeled Probes: Detecting And Discriminating Mycobacterium Tuberculosis Complex Members In Cultures And Animal Tissues. In: *Veterinary Infection Biology: Molecular Diagnostics and High-Throughput Strategies (Methods in Molecular Biology Series)*. Monica Cunha and João Inácio Editors. Humana Press, Springer Science+Business Media, LLC. Londres, Reino Unido. Vol. 1247. (ISBN 978-1-4939-2003-7).
<http://www.springer.com/medicine/internal/book/978-1-4939-2003-7>
19. Rodrigues L., **Viveiros M.**, and Aínsa J. (2015) Measuring Efflux and Permeability in Mycobacteria. In: *Mycobacteria Protocols (Methods in Molecular Biology Series)*, Tanya Parish and David Roberts, Editors. Humana Press, Springer Science+Business Media, LLC. Londres, Reino Unido. 3rd edition., XII, 412 p.Vol. 1285. (ISBN 978-1-4939-2449-3).
<http://www.springer.com/life+sciences/microbiology/book/978-1-4939-2449-3>

PARTICIPATION AND COORDINATION OF RESEARCH PROJECTS:

As Coordinator (n=8):

1. 2004 - 2006 - Principal Investigator/Coordinator of the project - Fundação Calouste Gulbenkian - " Diagnóstico Rápido da Tuberculose Multiresistente na Grande Lisboa".
2. 2005 - 2007 - Principal Investigator/Coordinator - Fundação para a Ciencia e Tecnologia - 1ST PHASE - (POCTI/SAU-MMO/59370/2004)" Bombas de Efluxo em M. tuberculosis: caracterização molecular dos mecanismos de efluxo e uso de inibidores de efluxo como novos compostos anti-bacilares - Efflux-pumps in M. tuberculosis: molecular charecterizatuion of the efflux mechanism and use of efflux inhibitors as new anti-TB drugs".
3. 2007 - 2009 - Principal Investigator/Coordinator - Fundação para a Ciencia e Tecnologia - 2ND PHASE - (PPCDT/SAU-MMO/59370/2004) "Bombas de efluxo em Mycobacterium tuberculosis: caracterização molecular dos mecanismos de efluxo e uso de inibidores de efluxo como novos compostos anti-bacilares - Efflux-pumps in drug resistance of Mycobacterium tuberculosis: Molecular characterisation of the efflux mechanism and use of efflux inhibitors as new anti-tubercular compounds".
4. 2008-2012 - Principal Investigator/Coordinator - Fundação Calouste Gulbenkian - Projecto de apoio ao Plano Estratégico de Controlo da Tuberculose de Moçambique - Support for the Strategic Plan to Fight TB in Mozambique. Fundação Calouste Gulbenkian, Instituto de Higiene e Medicina Tropical, Instituto Nacional de Saúde Dr. Ricardo Jorge.
5. 2008 - 2011 - Principal Investigator/Coordinator - Fundação para a Ciencia e Tecnologia - (PTDC/BIAMIC/71280/2006) - Dinâmica fisiológica e mutacional da resistência aos antibióticos em Mycobacterium tuberculosis: a emergência da Tuberculose Multi-Resistente. - Mutational and physiological dynamics of drug resistance in Mycobacterium tuberculosis: the emergence of Multi-Drug Resistant Tuberculosis.
6. 2009 - 2013 - Principal Investigator/Coordinator - Fundação para a Ciencia e Tecnologia - (PTDC/SAUFCF/102807/2008) "Enhancing the killing of intracellular multi-drug resistant tuberculosis (MDRTB) by human macrophages: a new chemotherapeutic strategy to fight MDRTB".
7. 2009 - 2013 - Principal Investigator/Coordinator - Fundação para a Ciencia e Tecnologia - (PTDC/BIAMIC/105509/2008) "Helper compounds against multidrug resistant bacteria: revealing their mechanism of action".
8. 2012 - 2015 - Principal Investigator/Coordinator (Component IHMT/UNL) - "Formação em Diagnóstico Laboratorial de Tuberculose - ForDILAB TB". Projecto conjunto Fundação Calouste Gulbenkian, Instituto de Higiene e Medicina Tropical e Instituto Nacional de Saúde Dr. Ricardo Jorge - Fundação Calouste Gulbenkian (instituição proponente – Dr^a Maria Herminia Cabral - Parceiros: Instituto de Higiene e Medicina Tropical (Prof. Doutor Paulo Ferrinho, Prof. Doutor Isabel Leitão Couto e Prof. Doutor João Piedade) e Instituto Nacional de Saúde Dr. Ricardo Jorge (Professor Doutor José Calheiros e Dr^o Maria João Simões). Submetido ao Secretariado Executivo da Comunidade dos Países de Língua Portuguesa, no âmbito do Plano Estratégico de Cooperação em Saúde da CPLP.
Nota: Projecto com o apoio e patrocínio do Representante Especial para Tuberculose do Secretário Geral das Nações Unidas, Sua Ex^a o Presidente da República Portuguesa, Dr. Jorge Sampaio.

As Member of the Research Team (n=13):

1. 1992 - 1994 - Junior Researcher in the project - C.E.E./D.G.XII - "AIDS Clinical and Seroimmunological reevaluation of HIV-2 positive people of Guiné-Bissau"; (Contract Nº TS2 - 001- P(TT) - EEC)- Coordinator - Prof. Wanda Canas-Ferreira.
2. 1994 - 1997 - Researcher in the project - Fundação Calouste Gulbenkian - (Desp-FCG-05/01/1994) - "Estudo cooperativo internacional sobre a imunidade protectora em tuberculose: investigações clinico-epidemiológicas e laboratoriais relacionadas com perspectivas de novos métodos de diagnóstico e pesquisa de nova geração de vacinas" - Coordinator - Prof. Hugo Ayres Lopes David.
3. 1995 - 1998 - Researcher in the project - Comissão Nacional de Luta Contra a SIDA - National Committee Against AIDS -(Projecto Nº 9-1.10.6./94) -"Estudo da relação tuberculose-SIDA e dos problemas de transmissão da tuberculose nas populações de alto risco, com a introdução, desenvolvimento e aplicação prática de novos métodos de diagnóstico rápido da tuberculose". Coordinator - Prof. Hugo Ayres Lopes David.
4. 2002 - 2005 - Researcher in the project - Fundação Calouste Gulbenkian - (SDH.IC.I.01.17) - " Grupo de Trabalho para a Tuberculose na Grande Lisboa - TB-TASK-FORCE for Greater Lisbon" - Coordinator - Prof. Leonard Amaral.
5. 2002 - 2005 - Researcher in the project - Fundação Calouste Gulbenkian - " Pesquisa de novos marcadores de imunidade celular para a detecção precoce da infecção por Mycobacterium tuberculosis - New cellular immune markers for early detection of active TB" - Coordinator - Prof. Leonard Amaral.
6. 2002 - 2005 - Researcher in the project - Fundação para a Ciencia e Tecnologia - (POCTI/FCB/37579/2001)" A actividade antimicobacteriana dos derivados de fenotiazinas, uma alternativa efectiva contra M. tuberculosis resistente aos antibióticos - Phenothiazines as an effective alternative against MDRTB" - Coordinator - Prof. Leonard Amaral.
7. 2008 - 2011 - Member/Researcher in the EU Consortium/Action – “Cost Action BM0701 - Antibiotic Transport and Efflux : New Strategies to combat bacterial resistance (Acronym:ATENS) “ - European Science Foundation.
8. 2009 - 2012 - Researcher in the project –“Diagnóstico e Epidemiologia Molecular de M/XDR-TB na Grande Lisboa: a Detecção Precoce na Prevenção da Emergência e Disseminação de Estirpes de M. tuberculosis Extensivamente Resistentes. - Early Molecular Detection of M/XDRTB in the Great Lisbon Healthcare Region” - Fundação Calouste Gulbenkian - Serviço de Saúde e Desenvolvimento Humano – Ref. P-99934 - Programa de Apoio à Investigação na Área da Microbiologia Clínica. Coordinator - Prof. Isabel Couto.
9. 2010 - 2013 - Researcher in the project - Quadro de Referência Estratégico Nacional (QREN)- "Acompanhamento da sequenciação e validação de “primers”, anotação e sua validação, construção de uma "toolbox" de transcriptómica dirigida e implementação de ensaios de qRT-PCR de duas estirpes de Sphingomonas sp. produtoras de carotenoides". Coordinator - Biotech company - Biotrend,Lda.
10. 2010 - 2013 - Researcher in the project - Fundação para a Ciência e Tecnologia - (PTDC/CVT/111634/2009) – ZoonTB - Novas abordagens moleculares para a detecção e discriminação de membros do Complexo Mycobacterium tuberculosis associados a tuberculose animal e avaliação do potencial zoonótico destas espécies em Portugal” - Instituto Nacional de Recursos Biológicos, I.P. (INRB/MADRP) instituição proponente - Coordinator - Inv. Doutor João Inácio.

11. 2011 - 2014 - Researcher in the project - Fundação para a Ciência e Tecnologia - (PTDC/BIA-MIC/121859/2010) - “ Type-II NADH-menaquinone oxidoreductase (NDH-2) and the respiratory chain of *M. tuberculosis*: new therapeutic targets to fight tuberculosis.” - Grupo de Micobactérias da Unidade de Microbiologia do IHMT/UNL (instituição proponente). Parceiro: Fundação da Faculdade de Ciências e Tecnologia (FFCT/FCT/UNL). Coordinator - Prof. Isabel Couto.
12. 2013 - 2016 - Researcher in the project - Fundação para a Ciência e Tecnologia - (PTDC/IVC-COM/5016/2012) - “OSYRISH - Organizational and Informational System to Improve Healthcare Associated Infections management in a set of Hospitals -.” Unidade de Saúde Internacional do IHMT/UNL (instituição proponente). Parceiros: Hospitais de Lisboa e da CPLP. Coordinator - Prof. Luis Lapão.
13. 2015-2017 - Researcher in the project - Programa Iniciativas em Saúde Pública | EEA Grants - HAITool – A Toolkit to Prevent, Manage and Control Healthcare-Associated Infections in Portugal (EEA Grants 182DT3). Unidade de Saúde Internacional do IHMT/UNL (instituição proponente). Parceiros: Centro Hospitalar de Lisboa Oriental - Lisbon, Portugal e The University Hospital of Northern Norway, Tromsø, Norway. Coordinator - Prof. Luis Lapão.

EXPERIENCE AS SCIENTIFIC ADVISER/SUPERVISOR (N=36):

Post-doctoral fellows supervised or ongoing (n= 3)

Post-doctoral fellows co-supervised or ongoing (n= 3)

PhD Students supervised or ongoing (n= 4)

PhD students co-supervised or ongoing (n= 3)

MSc Students supervised or ongoing (n = 19)

BSc students supervised (n = 6)

1. 1995/1996 – Co-supervisor of Paulo Jorge Gonçalves de Bettencourt - Licenciatura Thesis in Engenharia Biotecnológica do Instituto Superior de Humanidades e Tecnologias (ISHT) / Universidade Lusófona – "- Supervisor Prof^a. Doutora Laura Brum
2. 1996/1997 - Supervisor of Patrícia Raquel Fernandes de Melo Moreira - Licenciatura Thesis in Microbiologia pela Escola Superior de Biotecnologia da Universidade Católica Portuguesa - "Avaliação do teste de diagnóstico *Mycobacterium tuberculosis* LCX Abbott para amostras extrapulmonares".
3. 1996/1997 - Supervisor of Susana Frazão Pinheiro - Licenciatura Thesis in Microbiologia pela Escola Superior de Biotecnologia da Universidade Católica Portuguesa - "Avaliação do teste de identificação MTB LCX Abbott para amostras pulmonares".
4. 2001/2002 - Supervisor of Ana Isabel Caldeira de Jesus - Licenciatura Thesis in Engenharia Biotecnológica da Universidade Lusófona - "Resistência à tetraciclina em *Escherichia coli* por mecanismos de extrusão";.
5. 2003/2004 - Supervisor of Mafalda Lopes Brito - Licenciatura Thesis in Engenharia Biotecnológica do Instituto Superior Técnico da Universidade Técnica de Lisboa - "Resistência aos antibióticos em *Staphylococcus aureus* e *Escherichia coli* por mecanismos de extrusão".
6. 2003/2004 - Supervisor of - Francisco Estrela de Soure Dores - Licenciatura Thesis in Biologia Microbiana da Faculdade de Ciências de Lisboa - "Isolamento, purificação e caracterização de uma fracção proteica do envelope celular de *Staphylococcus aureus* associada à adaptação a elevadas concentrações de brometo de etídio".
7. 2004/2005 - Supervisor of Maria João Lobo da Cruz Rocha Monteiro Caetano - MSc in Medical Microbiology Thesis (IHMT/UNL) -"Diagnóstico molecular de micobacterioses em pacientes co-infectados com o VIH. Importância clínica, laboratorial e epidemiológica (em colaboração com o Hospital Egas Moniz)".
8. 2004/2005 - Supervisor of Liliana Isabel Dias Rodrigues- MSc in Medical Microbiology Thesis (IHMT/UNL) - "Diagnóstico precoce da tuberculose multiresistente na Grande Lisboa".
9. 2006/2007 - Supervisor of - Ana Laura Paixão - "Modelação do efluxo de Brometo de Etídio em *Escherichia coli*" . MSc in Biological Engineering from Instituto Superior Técnico da Universidade Técnica de Lisboa .
10. 2006/2007 - Supervisor of Ana Daniela de Araújo Sampaio - MSc in Medical Microbiology Thesis (IHMT/UNL)- "A contribuição da resistência fenotípica na resistência aos tuberculostáticos no género *Mycobacterium*" .
11. 2006/2007 - Supervisor of Ana Catarina Heitor Martins Cardoso - MSc in Medical Microbiology Thesis (IHMT/UNL)- "Efluxo de compostos fluorescentes em *Escherichia coli* e sua correlação com a resistência clínica aos antibióticos."

12. 2006/2007 - Co-supervisor of Sofia Maria Mourão Marques dos Santos Costa – MSc in Medical Microbiology Thesis (IHMT/UNL)- “Caracterização de proteínas do envelope celular de *S. aureus* associadas ao efluxo de compostos biocidas”.
13. 2007/2008 - Supervisor of Nadia Borges Charepe - MSc in Biomedical Sciences Thesis (IHMT/UNL) - “Estudo biológico dos mecanismos de resistência aos antibióticos desenvolvido em *Escherichia coli* sujeita a pressão antibiótica prolongada”.
14. 2008/2009 - Supervisor of Jorge Alexandre dos Santos Ramos – MSc in Medical Microbiology Thesis (IHMT/UNL)- “Avaliação do efeito sinérgico de inibidores de bombas efluxo na susceptibilidade do género *Mycobacterium* aos tuberculostáticos”.
15. 2008/2009 - Supervisor of Susana Cristina Nunes Costa – MSc in Medical Microbiology Thesis (IHMT/UNL)- “Caracterização bioquímica e molecular do efluxo de Brometo de Etídeo em *Escherichia coli*”
16. 2004/2008 - Co-supervisor of Marta Martins (SFRH/BD/14319/2003) - PhD Thesis in Medical Microbiology of IHMT/Universidade Nova de Lisboa - "The antimycobacterial activity of thioridazine derivatives, against Drug Resistant *Mycobacterium tuberculosis*. In vitro, ex vivo and in vivo studies".- Supervisor Prof. Doutor Leonard Amaral.
17. 2004/2008 - Co-supervisor of Ana Sofia Fernandes Martins (SFRH/BD/19445/2004)– - PhD Thesis in Medical Microbiology of IHMT/Universidade Nova de Lisboa - “The effects of *Carpobrotus edulis* methanol extract and purified compound(s) against multi-drug resistant *Mycobacterium tuberculosis* strains” - Supervisor Prof. Doutor Leonard Amaral.
18. 2006/2010 - Supervisor of Liliana Isabel Dias Rodrigues (SFRH/BD/24931/2005) - PhD Thesis in Medical Microbiology of IHMT/Universidade Nova de Lisboa - “The role of the efflux mechanisms in Multi-drug Resistance in *Mycobacterium tuberculosis*”.
19. 2009/2014 - Supervisor of Diana Isabel Oliveira Machado (SFRH/BD/65060/2009) - PhD Thesis in Medical Microbiology of IHMT/Universidade Nova de Lisboa - “The The dynamics of drug resistance in *Mycobacterium tuberculosis*: exploring the biological basis of multi- and extensively drug resistant tuberculosis (MDR/XDRTB) as a route for alternative therapeutic strategies”.
20. 2009/2014 - Co-supervisor of - Pedro Miguel Nisa Costa (SFRH/BD/64136/2009) - PhD Thesis in Medical Microbiology of IHMT/Universidade Nova de Lisboa - “Novas abordagens moleculares para a detecção e diferenciação rápida de espécies do complexo *Mycobacterium tuberculosis* e avaliação do seu potencial zoonótico em Portugal”. - Supervisor Doutor João Inácio.
21. 2009/2010 – Co-supervisor of Miguel José Simas do Rosário Evaristo – MSc in Biomedical Sciences Thesis (IHMT/UNL) - “Biological activity of well-defined heterocyclic compounds on efflux pump systems of bacteria and cancer cells”. - Supervisor Doutora Gabriella Spengler.
22. 2010/2014 - Post-Doc Supervisor of - Marta Sofia Lopes Martins (SFRH/BPD/63871/2009) - Post-Doc program in Medical Microbiology of IHMT/Universidade Nova de Lisboa - “Targeting the human macrophage with combinations of second-line TB drugs and inhibitors of Ca²⁺ and K⁺ transport to enhance the killing of intracellular Multi-Drug Resistant *M. tuberculosis* (MDR-TB) – a novel approach to limit the emergence of XDRTB”.

23. 2010/2011 - Co-supervisor of Lisa Santos Machado – MSc in Medical Microbiology Thesis (IHMT/UNL) - “The inhibitory activity of synthetic compounds and ions against transporters of multi-drug resistant bacteria”. - Supervisor - Professor Doutor Leonard Amaral.
24. 2010/2011 - Supervisor of Antónia Rosa Trindade Pinto – MSc in Biomedical Sciences Thesis (IHMT/UNL) - O Efluxo em *Escherichia coli*: novas estratégias terapêuticas para combate à multi-resistência.”
25. 2010/2011 - Co-supervisor of Vanessa Roque Cabral – MSc in Química Farmacêutica e Terapêutica da Faculdade de Farmácia da Universidade de Lisboa - “Efflux pump inhibitors in multidrug resistant bacterial strains from medicinal plants”. Supervisor - Professora Doutora Maria José Umbelino Ferreira.
26. 2010/2011 – Co-supervisor of Ana Carolina Vencá – MSc in Biotecnologia do Instituto Superior Técnico da Universidade Técnica de Lisboa, “Identification and characterisation of efflux pumps in *Rhodococcus erythropolis*.” Supervisor - Doutora Carla C.C.R. de Carvalho.
27. 2011/2013 - Co-supervisor of Nureisha Abdul Gafur Cadir – MSc in Saúde Pública da Faculdade de Medicina da Universidade Eduardo Mondlane – Mozambique - “Avaliação do desempenho dos testes imunocromatográficos rápidos (BD MGIT Tbc Identification Test e TB Ag MPT64 Device) para a diferenciação do Complexo *M. tuberculosis* das Micobactérias Não Tuberculosas”. Supervisores - Professor Doutor Mohsin Sidat e Doutor Eduardo Samo Gudo.
28. 2012/2015 - Post-Doc Supervisor of Paulo Rabna (SFRH/BPD 64/2011) Instituto Nacional de Saúde Pública da Guiné-Bissau - “Tuberculose Multirresistente na Guiné-Bissau ”.
29. 2012/2013 – Supervisor of Vânia Filipa Ferreira da Silva – MSc in Biomedical Sciences Thesis (IHMT/UNL) – “Estudo de determinantes de efluxo em *Mycobacterium avium* e a sua relação com a resistência aos antibióticos.” Co-supervisor – Professora Isabel Couto.
30. 2013/2014 – Co-supervisor of Ana Luísa Chocalheiro – MSc in Biotecnologia da Faculdade de Ciências e Tecnologia da Universidade Nova de Lisboa, “Application of Lab-on-Paper technology to colorimetric biosensors for the detection of tuberculous mycobacteria.” Supervisor – Professora Doutora Elvira Fortunato.
31. 2013/2014 – Co-supervisor of André Meneses Valério – MSc in Engenharia Biomédica da Faculdade de Ciências e Tecnologia da Universidade Nova de Lisboa, “Desenvolvimento de testes de susceptibilidade a antibióticos do tipo E-tests em suportes de papel utilizando a tecnologia lab-on-paper” Supervisor – Professora Doutora Elvira Fortunato.
32. 2013/2017 - Supervisor of Moisés Franciso - PhD Thesis in Medical Microbiology of IHMT/Universidade Nova de Lisboa - “Caracterização microbiológica e molecular das estirpes de Salmonella spp isoladas em amostras de fezes, águas residuais e em ovos de produção aviárias na região de Luanda e dos seus perfis de resistência aos antimicrobianos – o seu impacto na saúde pública.”
33. 2015/2018 - Supervisor of Ana Maria Buttle de Mendonça Mourão Possidónio de Armada - PhD Thesis in Human Genetics and Infectious Desiases of IHMT/Universidade Nova de Lisboa - “Modulation of ABC transporters in multidrug resistance (MDR): From prokaryotic to eukaryotic cells.”
34. 2014/2017 - Post-Doc Co-Supervisor of – João Ruben Lucas Mota Perdigão (SFRH/BPD/95406/2013) - Post-Doc program in Microbiology of Pharmacy Faculty/Universidade de Lisboa - “Tuberculosis in Portugal and Portuguese-speaking African Countries: From Genomics to Product Development”. Supervisor – Professora Doutora Isabel Portugal.

35. 2014/2015 - Supervisor of Ana Sofia Mourão Simões – MSc in Medical Microbiology Thesis (IHMT/UNL) - “Characterization of drug resistance mechanisms underlying colistin heteroresistance in clinical isolates of *Acinetobacter baumannii*”.
36. 2015/2018 - Post-Doc Supervisor of - Diana Isabel Oliveira Machado (SFRH/BPD/100688/2014) - Post-Doc program in Medical Microbiology of IHMT/Universidade Nova de Lisboa - “Exploring the mode of action of efflux inhibitors against *Mycobacterium tuberculosis*: an approach to prevent efflux-mediated resistance and boost therapy in active and latent tuberculosis”.
14. 2015/2016 - Post-Doc Co-Supervisor of – Alexandra Simões - Post-Doc program in Medical Microbiology of IHMT/Universidade Nova de Lisboa - “Using molecular, epidemiological, clinical and social data to prevent and control antibiotic resistant healthcare-associated infections”. Programa Iniciativas em Saúde Pública | EEA Grants - HAITool – A Toolkit to Prevent, Manage and Control Healthcare-Associated Infections in Portugal (EEA Grants 182DT3). Unidade de Saúde Internacional do IHMT/UNL (instituição proponente). Parceiros: Centro Hospitalar de Lisboa Oriental - Lisbon, Portugal e The University Hospital of Northern Norway, Tromsø, Norway. Main-supervisor and Coordinator – Investigador Doutor Luis Lapão.
15. 2014/2015 – Supervisor of Marta Isabel Martins Gabriel – MSc in Biomedical Sciences Thesis (IHMT/UNL) – “Resposta imunitária inflamatória de macrófagos na presença de inibidores de efluxo.” Co-supervisors – Professora Gabriela Santos-Gomes e Investigadora Ana Maria Buttle de Mendonça Mourão Possidónio de Armada.

AWARDS:

2003 – Merit Award for Research in Infectious Diseases (2° Place) - Glaxo-Smithkline Fundation – Portuguese Society of Infectious Diseases - “A Implementação do Programa “TB-FAST-TRACK” de Combate à Tuberculose Multiresistente na Grande Lisboa - Implementantion of the TB-FAST-TRACK program in Lisboa”.

2009 – Merit Award for Best Panel Communication National Congress of Microbiology and Biotechnology - Congresso Nacional de Microbiologia e Biotecnologia de 2009 d- “Cell and Tissue Engineering, Biomaterials and Nanobiotechnologies”. Authors: Veigas B., Perdigão J., Portugal I., Couto I., Viveiros M. and Baptista P.V. (2009) Use of Au-nanoprobes for the detection of SNPs associated with antibiotic resistance in Mycobacterium tuberculosis. Congresso Microbiotec 2009. Congresso Nacional de Microbiologia e Biotecnologia MicroBiotec09. Vilamoura (Portugal) 28 a 30 de November de 2009.

2012 – Santander/Totta – Universidade Nova de Lisboa - Merit Award 2012 - Prémio de Mérito Científico Santander Totta – Universidade Nova de Lisboa – Title: NanoTB - Nanodiagnostics for XDRTB at point-of-need. Miguel Viveiros (IHMT/UNL), Pedro Baptista (FCT/UNL), Isabel Couto (IHMT/UNL).

SELECTED INVITED LECTURES (N=18):

1. **Viveiros M.** (2009). Evaluation of efflux pumps of Mycobacteria by a semi-automated EB method. Invited Speaker at COST Action BM0701: Antibiotic Transport and Efflux: New Strategies to combat bacterial resistance (ATENS), Cracovia (Polónia), a 18 may 2009.
2. **Viveiros M.** (2010). Cutaneous infections caused by mycobacteria. Invited Speaker at the Spring Meeting of the Portuguese Society of Dermatology and Venereal Diseases.. V. N. Gaia (Portugal), 23 - 24 April 2010.
3. **Viveiros M.** (2011). Atypical Mycobacteriosis - Infecções por micobacterias atípicas Invited Speaker at the XII Jornadas Nacionais de Infecçologia Pediátrica. Braga (Portugal), 19 - 21 de May 2011.
4. **Viveiros M.** (2011). Direct detection of resistance in Mycobacterium tuberculosis: from line to nano-probe assays. Invited Speaker at the World TB Day Conference - Contribution of scientific research in the fight against tuberculosis. Institute of Tropical Medicine, Antwerpia, (Belgica), a 22 de Março de 2011.
5. **Viveiros M.** (2011). Resistencia fisiológica em Mycobacterium tuberculosis: impacto na resistência adquirida e novas estratégias quimioterapeúticas adjuvantes Invited Speaker at the Simpósio Internacional de Tuberculose Avanços e desafios no século XXI 02 e 03 de Dezembro de 2011.
6. **Viveiros M.** (2012). Cost-efficient diagnosis of tuberculosis: culture, molecular techniques and immunological markers. Invited Speaker at the European Congress of Clinical Microbiology and Infectious. 22nd European Congress of Clinical Microbiology and Infectious Diseases, London, United Kingdom, 31 March – 3 April 2012.
7. **Viveiros M.** (2012). Test de susceptibilidad cuantitativo de 1^a y 2^a línea para Mycobacterium tuberculosis usando lo BACTEC MGIT 960 con software TB eXiST : un protocolo en desarrollo en Europa. Invited Speaker at the XVI Reunion del grupo español de Micobacteriologia - GEM 2012. Cordoba 22 – 24 March 2012
8. **Viveiros M.** (2012). The semi-quantitative drug susceptibility test of 1st and 2nd line drugs for Mycobacterium tuberculosis using the MGIT 960TBTM culture system coupled with the BD EpiCenter™ TB-eXiST software. XIV Simpósio Brasileiro de Micobactérias - XXI Congresso Latinoamericano de Microbiología. Santos, São Paulo, Brasil. 1-5 November 2012.
9. **Viveiros M.** (2013). Significance of Efflux in Multidrug resistance in Mycobacterium tuberculosis. Invited Speaker at the Gordon Research Conferences. Multi-Drug Efflux Systems. Shared Molecular Mechanisms but Diverging Roles in Physiology and Medicine. Four Points Sheraton / Holiday Inn Express, Ventura, (CA, USA), March 17-22.
10. **Viveiros M.** (2013). Epidemiology of infections due to NTM. Speaker at the Infections due to non-tuberculous mycobacteria: Educational Workshop – 23rd European Congress of Clinical Microbiology and Infectious (ECCMID). European Congress of Clinical Microbiology and Infectious Diseases, Berlin (Germany), 31 March to 3 April 2013.
11. **Viveiros M.** (2013) O Projecto FORDILAB-TB Formação em Diagnóstico Laboratorial de Tuberculose no espaço da CPLP. Seminar: Innovations for Tuberculosis Control, Maputo (Mozambique) 14 – 16 May 2013.
12. **Viveiros M.** (2013) "Estética y MNT. Un problema emergente en Portugal". XVII Taller Internacional sobre Tuberculosis, Barcelona (Spain) 4 – 5 November 2013.
13. **Viveiros M.** (2014) Efflux inhibitors as adjuvants in drug resistant tuberculosis therapy. World's Tuberculosis day international conference, Ghent University "Het Pand", Gent, Belgium. 21st March 2014.

14. **Viveiros M.** (2014). How to diagnose mycobacterial infections in low-income countries: Educational Workshop – Invited Speaker at the 24th European Congress of Clinical Microbiology and Infectious (ECCMID). European Congress of Clinical Microbiology and Infectious Diseases, Barcelona (Spain), 10th May 2014.
15. **Viveiros M.** (2014) Efflux inhibitors against drug resistant *Mycobacterium tuberculosis*: adjuvants of antimycobacterial agents and enhancers of macrophage killing activity. Invited Speaker at the VII Meeting of the Latin-American Society of Tuberculosis and other Micobacteriosis (SLAMTB), Canela, Brazil. 15th September 2014.
16. **Viveiros M.** (2014) Programatic Implementation of Molecular Tests for TB diagnoses in low and middle income countries – Challenges and Perspectives. Invited Speaker at the IV National Workshop of Brazilian Tuberculosis Research Network (REDETB), Canela, Brazil. 15th September 2014.
17. **Viveiros M.** (2014) Infecções respiratórias: tuberculose pulmonar - novos métodos de identificação e detecção de resistências - I Jornadas do Médico Interno de Patologia Clínica. Ordem dos Médicos, Lisboa, Portugal, 26th September 2014.
18. **Viveiros M.** (2015) Efflux Modulators as Adjuvants of Anti-Tuberculosis Therapy and Enhancers of Macrophage Killing Activity: A New Concerted Strategy Against Drug Resistant *Mycobacterium tuberculosis*. Invited Speaker at the Gordon Research Conferences. Multi-Drug Efflux Systems: A Paradigm Shift from Fundamental Mechanisms to Practical Applications. Renaissance Tuscany Il Ciocco Resort; Lucca (Barga), Italy, April 26th-May 1st.

CONFERENCE ORAL AND POSTER COMMUNICATIONS (N= >150).